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Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies 
are a heterogeneous population of membrane particles released by cells to the extracellular 
space and into biofluids during normal physiological and pathological processes. EVs have 
been recognized as powerful vehicles for intercellular communication due to their capacity to 
transfer lipids, proteins, and nucleic acids, thereby influencing the properties and functions 
of recipient cells. Cells generate EVs with a unique composition based on their 
characteristics, which has a special relevance in the study of diseases such as cancer. Since 
specific molecular signatures can be passed on to tumor EVs, they are prime candidates for 
implementation as cancer biomarkers and in the delivery of therapeutics. Thus, exhaustive 
research is currently targeted towards elucidating the role of EVs in cell-to-cell 
communication and their therapeutic and diagnostic use.  
This thesis aims at broadening our understanding of the applicability and functional 
relevance of the use of EVs as prostate cancer biomarkers and therapeutic delivery vehicles. 
First, the practical use of EVs as a source of nucleic acid biomarkers in prostate cancer was 
assessed by exploring the DNA and RNA content of vesicles. Genomic DNA analysis of 
apoptotic bodies, microvesicles, and exosomes were performed to detect mutations within 
the EV cargo. The results were validated in plasma EVs of prostate cancer patients, from 
which the presence of prostate cancer-relevant genes was identified. Next, the prostate 
cancer-specific messenger RNA signatures of microvesicles and exosomes were analyzed. 
Unique nucleic acid signatures distinctive for the cell origin were found in the form of 
differential levels of mRNA transcripts from EV subpopulations. Overall, the nucleic acid 
content of EVs provided a new source of diagnostic information that could contribute to early 
prediction and diagnosis of prostate cancer, especially if combined. The role of EV-mediated 
intercellular communication was shown by comparing the uptake efficiencies and functional 
effects of EVs from prostate cancer cells of different metastatic status with non-cancer EVs. 
Additionally, the ability of EVs to carry and deliver a chemotherapeutic drug, together with 
their cytotoxic effects on prostate cancer cells were also analyzed. While EV uptake, in 
general, was an active and continuous process, the internalization rate and the subsequent 
functional effects of EVs on recipient cells differed based on the vesicle origin. EVs derived 
from cells of a metastatic source were more efficiently internalized than primary prostate 
cancer or benign prostate epithelial cell-derived EVs. Similarly, those EVs also induced a 
more proliferative and migratory phenotype in the recipient cells. Applying prostate cancer 
EVs in the in vitro delivery of paclitaxel to prostate cancer cells, resulted in an enhanced 
cytotoxic effect of paclitaxel mediated by EV delivery compared to the free drug. 
In summary, the results presented in this thesis support the concept that EVs can be 
utilized in both biomarker discovery and drug delivery fields as multifunctional tools for 
diagnosis and treatment of diseases such as prostate cancer. The studies presented here will 
also contribute to set the bases for further functional analysis of the roles of EVs in cell-to-cell 
communication. This new era of research could lead to faster, non-invasive, and more 
individualized diagnosis and improved treatments tailored to the specific needs of the 
patients. 
ii 
 
?????????????????
This doctoral thesis has been a challenge to me both on an academic and personal level. It 
marks one of the most important stages of my life, where all the people who have supported 
and encouraged me have been a fundamental pillar. I only have words of gratitude to all the 
wonderful people I met over the years and those who have always been there. 
 
The work presented in this thesis was carried out at the Centre for Drug Research (CDR), 
Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki. Part of 
the work was undertaken at the Krefting Research Center (KRC), University of Gothenburg. 
 
I first would like to thank Prof. Jouni Hirvonen, the Dean of the Faculty of Pharmacy, Prof. 
Heikki Vourela, head of the Division of Pharmaceutical Biosciences, and Prof. Arto Urtti, 
head of CDR and the former head of the Division of Pharmaceutical Biosciences, for 
providing research facilities and educational opportunities. Also the director and coordinator 
of the Doctoral School in Health Sciences Prof. Hannu Sariola and Doc. Eeva Sievi, and the 
director and coordinator of the Doctoral Program in Drug Research Prof. Heikki Ruskoaho 
and PhD. Ilkka Reenilä are warmly acknowledged. Maija Tiippana, Elisa Sippola, Tarja 
Viskari, and Eija Raitanen are thanked for their academic and administrative support. 
 
I am honored that Prof. Janusz Rak from the McGill University of Montreal has accepted the 
invitation to be my opponent in the public defense of this thesis. I would like to thank the 
reviewers of this thesis PhD Alicia Llorente from Oslo University Hospital and PhD Carla 
Oliveira from the University of Porto for their comments and useful suggestions that helped 
me to improve this thesis. My gratitude goes also to the members of my steering committee; 
Prof. Jorma Keski-Oja, and Adj. Profs. Vincenzo Cerullo and Pirkko Mattila. 
 
I am extremely grateful to my supervisors Prof. Marjo Yliperttula, PhD. Carmen Escobedo-
Lucea and Adj. Prof. Pia Siljander, and as well as to Prof. Jan Lötvall for their unconditional 
support and guidance through my PhD studies. Marjo, you brought me from Spain to Finland 
to do my PhD studies in your group, in the novel and challenging field of extracellular 
vesicles. I would like to sincerely thank you for such a fantastic opportunity. Over the years, 
you have always believed and trusted me, offering me opportunities to grow as an 
independent scientist. You taught me to have an overall view of science and your support 
throughout this PhD has been fundamental. Carmen, your dedication to science is sincerely 
admirable and something I wish I can one day emulate. Your unconditional advice, priceless 
support, and guidance are truly invaluable and what kept me going through this, not always 
easy, PhD. You have taught me that hard work always brings a reward, and I know that you 
will always be there for me. Pia, I cannot thank you enough for your commitment and 
kindness to me. Thank you for extending guidance all the way through the PhD and your 
invaluable help that made this thesis possible. As a supervisor, you are truly inspirational to 
me, and I’m eternally grateful for everything you’ve taught me, which really is a lot. Jan, you 
welcomed me to your lab and provided me the opportunity to work on new projects that were 
a breath of fresh air to me. I spent the last year of my PhD in your lab, and that time helped 
me grow both scientifically and personally. I learnt so many things from you. It has been a 
fantastic time. Thanks for trusting and always supporting me. 
 
I would like to acknowledge the multiple founding sources that made this work possible: 
University of Helsinki, Finnish Cultural Foundation, Academy of Finland, SalWe, the Finnish 
iii 
 
Funding Agency for Innovation (Tekes), Oskar Öflunds Stiftelse, Finnish Pharmaceutical 
Society, K. Albin Johanssons Stiftelse, Doctoral Program in Drug Research (DPDR), 
European Cooperation in Science and Technology Program (COST), Assar Gabrielssons 
Fond, and Association of Pharmacy Teachers and Researchers. All the co-authors are deeply 
acknowledged for sharing their expertise and contributing to this work. Jorge, Dominique, 
and Chris are thanked for their contributions with editing this thesis. 
 
One of my best experiences from this period was the privilege to meet many different people 
from countries all around the world. You all taught me so much about life and ignited my 
curiosity to travel. I loved to work in such an international and cheerful atmosphere both in 
Finland and in Sweden. 
 
It was a pleasure to work with all my present and former colleges in the Division of 
Pharmaceutical Biosciences: Polina, Leena Pietilä, Melina, Astrid, Andrés, Noora, Mecki, 
Tatu, Liisa, Ansku, Otto, Leena K, Madhu, Sanjay, Johanna, Jaakko, Cristian, Patrick, Eva, 
Aniket, Mari, Manlio, Marco, Andy, Lukasz, Mariangela, Petter, Teemu, Feng, Erja, Timo, 
Alma, Tappi, and Yan-Ru. Thanks for creating such a friendly and great working atmosphere 
and for sharing everyday life with me.  
 
I wish to express my deepest gratitude to all my talented colleagues who form the EV group: 
Heikki, Katri Maarit, Sami, Maarit, Mari, and Maria. Thanks for caring so much and for all 
the support I received from you during these years. It has been a pleasure to work with you 
all. You have all made this journey special.  
 
I am very grateful to all my colleagues and friends from KRC, especially to Patty, Barbora, Su 
Chul, Ross, Cecilia, Taral, Ganesh, Aleksander, Yunqian, Shintaro, Kyong-Su, Elga, Kristina, 
Carina, Madelaine, Linda, and Eva-Marie. You made me feel integrated in the KRC family 
from the first day I moved to Gothenburg. You are all amazing people both scientifically and 
personally, and it has been a true pleasure to share my working life and fun moments with 
you. I have learnt so much, and it’s all thanks to you! 
 
I would also like to thank my friends from Pharmaceutical Technology: Barbara, Alexandra, 
Giulia, Mónica, Patrick, Sami, and Ali for always cheering me up, and my dearest friends 
Saija, Anni, Jorge, Carla, Mar, Eva, Cristina, Maria, Sandra, Silvia, Marta, and Vergara for 
their priceless friendship and emotional support over the years.  
 
Last but not least, I would like to express my everlasting gratitude to my family. Mamá y 
papá, gracias por guiarme a través de la vida. Vosotros sois la razón de mi éxito y me esfuerzo 
todos los días para haceros sentir orgullosos. Gracias a mi hermana Carmen y a mi iaia 
Carmen por vuestro apoyo y cariño incondicional. Staffan, I cannot thank you enough. Your 
love, optimistic attitude, and unconditional support is what kept me going. Life is best when 
you are around. Thank you for loving me and making me extremely happy.  
 
 
 
Helsinki, February 2017 
Elisa Lázaro Ibáñez 
 
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
v 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One, remember to look up at the stars and not down at your feet. Two, never give up work. 
Work gives you meaning and purpose and life is empty without it. Three, if you are lucky 
enough to find love, remember it is there and don’t throw it away. ― Stephen Hawking 
  
vi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
vii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my parents 
  
viii 
 
??????????????????
Abstract ...................................................................................................... i?
Acknowledgements .................................................................................... ii?
Table of contents ..................................................................................... viii?
List of original publications ....................................................................... x?
Personal contribution ............................................................................... xi?
Additional publications ............................................................................ xii?
Abbreviations .......................................................................................... xiii?
1? Introduction ........................................................................................ 1?
2? Literature review ................................................................................ 2?
2.1? Extracellular vesicles ............................................................................................. 2?
2.1.1? The emergence of EVs in life sciences ......................................................... 2?
2.1.2? Biogenesis and secretion of EVs ................................................................... 3?
2.1.3? Molecular composition of EVs ...................................................................... 5?
2.1.4? EVs as mediators of cell-to-cell communication .......................................... 7?
2.1.5? Physiological and pathological functions of EVs ......................................... 8?
2.2? EVs in cancer ......................................................................................................... 9?
2.2.1? Role of EVs in the hallmark functions of cancer ......................................... 9?
2.2.2? EVs in cancer diagnosis and prognosis ....................................................... 14?
2.3? Prostate cancer ..................................................................................................... 17?
2.3.1? Current diagnosis and treatment ................................................................ 17?
2.3.2? EVs as prostate cancer biomarkers ............................................................. 18?
2.4? Therapeutic potential of EVs ............................................................................... 21?
2.4.1? Harnessing the intrinsic functions of EVs for therapeutics ....................... 21?
2.4.2? EVs in drug delivery ................................................................................... 22?
2.5? Prospects of EVs as cancer biomarkers and drug delivery carriers ................... 24?
3? Aims of the study .............................................................................. 26?
4? Materials and Methods ...................................................................... 27?
4.1? Cell lines and culture conditions (I, II, III, IV) .................................................... 27?
4.2? Patient samples (I) ............................................................................................... 27?
4.3? Antibodies (II, III, IV) ......................................................................................... 28?
4.4? EV isolation (I, II, III, IV) ................................................................................... 28?
4.4.1? Differential centrifugation ......................................................................... 28?
4.5? EV characterization (I, II, III, IV) ....................................................................... 30?
4.5.1? Transmission electron microscopy (I, II, III, IV) ...................................... 30?
4.5.2? Nanoparticle tracking analysis and zeta potential (I, III, IV) ................... 30?
4.5.3? Protein content and Western blotting (I, II, III, IV) ................................. 30?
4.5.4? Fluorescent labeling and flow cytometry (III, IV) ...................................... 31?
4.5.5? DNA analysis (I) .......................................................................................... 31?
4.5.6? mRNA analysis (II) ...................................................................................... 31?
4.6? EV drug-loading and delivery (IV) ...................................................................... 32?
4.7? In vitro cell-based assays (III, IV) ...................................................................... 32?
4.7.1? EV uptake and intracellular trafficking (III, IV) ........................................ 32?
4.7.2? Cell viability (III, IV) .................................................................................. 33?
ix 
 
4.7.3? Cell cycle (III) ............................................................................................. 33?
4.7.4? Proliferation (III) ........................................................................................ 34?
4.7.5? Migration (III) ............................................................................................ 34?
4.8? Statistical analysis (I, II, III, IV) ......................................................................... 34?
5? Results .............................................................................................. 35?
5.1? Prostate cancer cells release distinct EV subpopulations (I, II, III, IV) ............ 35?
5.1.1? Characteristics of prostate EVs .................................................................. 35?
5.1.2? Differential nucleic acid cargo of EVs ........................................................ 36?
5.2? EVs contain double-stranded gDNA harboring prostate cancer mutations (I) .. 37?
5.3? Specific prostate cancer mRNA signatures of EVs (II) ...................................... 38?
5.4? Uptake and functionality of prostate cancer EVs depends on the metastatic 
stage of the parent cells (III, IV) ............................................................................................ 40?
5.5? EV-mediated paclitaxel delivery enhances the cytotoxicity of the drug (IV) ..... 43?
6? Discussion ........................................................................................ 46?
6.1? EV-nucleic acid cargo as an emerging source of prostate cancer biomarkers ... 46?
6.1.1? Oncogenic DNA content of EVs .................................................................. 47?
6.1.2? EV-associated mRNA in the detection of prostate cancer ......................... 48?
6.2? Towards elucidating the role of EV-mediated cell-to-cell communication ....... 50?
6.2.1? Contribution of EVs to prostate cancer progression ................................. 50?
6.3? EVs as emerging targets for drug delivery .......................................................... 52?
7? Conclusions ...................................................................................... 54?
8? Future prospects ................................................................................ 55?
9? References ......................................................................................... 57?
?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
??????????????????????????????
 
This thesis is based on the following publications, which are referred to in the text by 
roman numerals (I-IV). 
 
 
I Lázaro-Ibáñez E., Sanz-Garcia A., Visakorpi T., Escobedo-Lucea C., Siljander P., 
Ayuso-Sacido Á*., Yliperttula M*. Different gDNA content in the subpopulations of 
extracellular vesicles: Apoptotic bodies, microvesicles, and exosomes. Prostate. 
74(14):1379-90, 2014. 
 
 
II Lázaro-Ibáñez E., Lunavat T.R., Jang SC., Escobedo-Lucea C., Oliver-De la Cruz 
J., Siljander P., Lötvall J*., Yliperttula M*. Distinct prostate cancer-related mRNA 
cargo in extracellular vesicle subsets from prostate cell lines. BMC cancer. 17 (1):92, 
2017.  
 
 
III Lázaro-Ibáñez E., Neuvonen M., Takatalo M., Thanigai Arasu U., Capasso C., 
Rhim JS., Rilla K., Yliperttula M., Siljander P. Metastatic state of parent cells 
influences the uptake and functionality of prostate cancer cell-derived extracellular 
vesicles. Submitted. 
 
 
IV Saari H*., Lázaro-Ibáñez E*., Viitala T., Vuorimaa-Laukkanen E., Siljander P., 
Yliperttula M. Microvesicle- and exosome- mediated drug delivery enhances the 
cytotoxicity of Paclitaxel in autologous prostate cancer cells. Journal of Controlled 
Release. 28;220, (Pt B):727-37, 2015. *Equal contribution. 
 
 
 
 
 
 
 
 
Reprinted with the kind permission of the publishers. 
xi 
 
??????????????????????
 
Publication I 
The author contributed to the experimental design of the study, performed all the 
experiments, contributed to the analysis and interpretation of the data, and wrote the 
manuscript with co-authors. 
 
Publication II 
The author conceived and designed the study, conducted all the experiments, and 
collected and analyzed the data. The author wrote the manuscript with co-authors. 
 
Publication III 
The author conceived and designed the study with contributions from co-authors. The 
author performed the extracellular vesicle isolation and characterization experiments, cell 
uptake, cell cycle, proliferation, and migration studies. The author co-analyzed the data, and 
wrote the manuscript with co-authors. 
 
Publication IV 
The author contributed to the experimental design of the study, performed the 
extracellular vesicle isolation and characterization experiments, and cell studies including 
uptake. The author interpreted and co-analyzed the data, and co-wrote the manuscript with 
co-authors. 
 
?
?
?
?
?
?
?
?
?
 
 
 
xii 
 
????????????????????????
List of additional publications not included in this thesis. 
 
 
García-Romero N*., Carrión-Navarro J*., Esteban-Rubio S*., Lázaro-Ibáñez E., Peris-
Celda M., Alonso M.M., Guzmán-DeVilloria J., Fernández-Carballal C., Ortiz de Mendivil A., 
García-Duque S., Escobedo-Lucea C., Prat-Acín R., Belda-Iniesta C., Ayuso-Sacido A. DNA 
sequences within glioma-derived extracellular vesicles can cross the intact Blood-Brain 
Barrier and be detected in peripheral blood of patients. Oncotarget. 8(1): 1416-28. 2016 
 
Mustonen A., Nieminen P., Joukainen A., Jaroma A., Kääriäinen T., Kröger H., Lázaro-
Ibáñez E., Siljander P.R-M., Kärjä V., Härkönen, K., Koistinen, A., and Rilla, K. First in vivo 
detection and characterization of hyaluronan-coated extracellular vesicles in human synovial 
fluid. J Orthop Res. 2016. 
 
Smith Z., Lee C*., Rojalin T*., Carney R*., Hazari S., Knudson A., Lam K., Saari H., Lázaro-
Ibáñez E., Viitala T., Laaksonen T., Yliperttula M., Wachsmann-Hogiu S. Single exosome 
study reveals subpopulations distributed among cell lines with variability related to 
membrane content. J Extracell Vesicles. 7;4:28533, 2015. 
  
Molina I., Lázaro-Ibáñez E., Pertusa J., Debón A., Martínez-Sanchís J.V., Pellicer A. A 
minimally invasive methodology based on morphometric parameters for day 2 embryo 
quality assessment. Reprod BioMed Online. 29(4):470-80, 2014.  
  
Oliver-De La Cruz J., Carrión-Navarro J., García-Romero N., Gutiérrez-Martín A., Lázaro-
Ibáñez E., Escobedo-Lucea C., Perona R., Belda-Iniesta C., Ayuso-Sacido A. SOX2+ cell 
population from normal human brain white matter is able to generate mature 
oligodendrocytes. PLoS ONE. 5;9(6): e99253. 2014. 
  
Perez-Garcia A., Carrion-Navarro J., Bosch-Fortea M., Lázaro-Ibáñez E., Prat-Acin R., 
Ayuso-Sacido A. Genomic instability of surgical sample and cancer-initiating cell lines from 
human glioblastoma. Front Biosci. 1;17:1469-79, 2012. 
 
 
  
 
*Equal contribution 
xiii 
 
???????????????
ABs   Apoptotic bodies 
Alix  ALG?2-interacting protein X 
CAFs  Cancer-associated fibroblast 
CFSE  Carboxyfluorescein succinimidyl ester 
Cryo-EM  Cryo-electron microscopy 
DiI   DiIC18(5)-DS 
DiO   SP-DiOC18(3) 
DNA  Deoxyribonucleic acid 
DPBS  Dulbecco's phosphate-buffered saline 
EGFR  Epidermal growth factor receptor 
ESCRT  Endosomal sorting complex required for transport 
EVs   Extracellular vesicles 
EXOs  Exosomes 
FASN  Fatty acid synthase 
FBS   Fetal bovine serum 
gDNA  Genomic deoxyribonucleic acid 
HIFs  Hypoxia inducible factors 
LOs   Large oncosomes 
miRNA  Micro ribonucleic acid 
mRNA  Messenger ribonucleic acid 
MSCs  Mesenchymal stem/stromal cells 
mtDNA  Mitochondrial DNA 
MVB  Multivesicular bodies  
MVs  Microvesicles 
NTA  Nanoparticle tracking analysis 
PCA-3  Prostate cancer antigen 3 
PCR  Polymerase chain reaction 
PI   Propidium iodide 
PSA   Prostate-specific antigen 
PSMA  Prostate-specific membrane antigen 
PTEN  Phosphatase and tensin homolog 
PtX   Paclitaxel 
RNA  Ribonucleic acid 
rRNA  Ribosomal ribonucleic acid 
RT-qPCR  Real-time quantitative polymerase chain reaction 
SFM  Serum free media 
TEM  Transmission electron microscopy 
TP53  Tumor protein p53 
TSG101  Tumor susceptibility 101 
UPLC  Ultra performance liquid chromatography 
 

Introduction 
 
 1  
 
?? ?????????????
 
The current diagnosis and development of cancer treatments is increasingly dependent 
on the understanding of the patient’s unique molecular and genetic characteristics. Predictive 
cancer biomarkers are crucial tools in personalized medicine, as they enable the selection of 
patients that are most likely to benefit from targeted therapies (Schork, 2015). A major 
challenge in personalized medicine is the identification of biomarkers with diagnostic and 
prognostic value. Despite the increased in research devoted to identifying new cancer 
biomarkers only a limited number have been approved for clinical use by the Food and Drug 
Administration (FDA) (Goossens et al., 2015). New cancer biomarkers are needed in order to 
predict patient survival, monitor the disease progression, and predict the response to 
therapies. Additionally, the development of novel cancer treatments and the customization of 
current therapeutic strategies are also important in order to increase the health outcomes of 
cancer patients. Drug delivery systems have been extensively used in the treatment of cancer 
as they improve the pharmacological properties of the drugs (Allen and Cullis, 2004). 
However, important limitations including reduced specificity, targeting, biocompatibility, 
and limited ability to penetrate tissues, are major drawbacks of some of the current drug 
delivery systems (Fais et al., 2016). 
The analysis of cancer-derived extracellular vesicles (EVs) has given new insights into 
the biomarker discovery and drug delivery fields. EVs are secreted as nature´s intercellular 
transport vesicles into blood, urine, and other biofluids, and thus, they interact with many 
diverse cell types, mediating physiological and pathological functions (Raposo and 
Stoorvogel, 2013; Yáñez-Mó, Siljander et al., 2015). The discovery that EVs carry an array of 
bioactive molecules such as lipids, proteins, and nucleic acids that can be shuttled between 
cells demonstrates the relevant participation of EVs in the complex framework of cell 
signaling and communication (Barry et al., 1997; Deregibus et al., 2007; Ratajczak et al., 
2006; Valadi et al., 2007). EVs released by cancer cells are known to participate in tumor 
development and in the acquisition of the cancer hallmark capabilities, having a clear impact 
on cancer-sustaining processes such as angiogenesis, tumor proliferation, invasion, and 
metastasis (Kanada et al., 2016; Rak, 2013). On that basis, EVs can be harnessed for cancer 
diagnostics, prognostics, and treatment monitoring. EV levels and their cargo, particularly 
proteins, RNA, and DNA, vary in different conditions and disease stages, reflecting the status 
of the cancer cells, thereby providing a snapshot of the tumor. EVs have also attracted 
considerable interest for their potential use as effective, targeted, and non-immunogenic 
therapeutic agents and drug delivery carriers (Ha et al., 2016; Stremersch et al., 2016a). 
Thus, elucidation of the molecular mechanisms that underlie the release and uptake of 
different EV subtypes, together with new strategies to specifically target cancer cells by EVs, 
will be essential to increase our understanding of the role of EVs in intercellular 
communication. This knowledge will also be an advantage for the design of engineered drug 
delivery vehicles by using EVs as a blueprint. 
This thesis aimed to assess the use of EVs as a potential source of biomarkers and as 
therapeutic drug carriers using prostate cancer as a disease model. First, the nucleic acid 
content of EV subpopulations, including genomic DNA (gDNA) and messenger RNA 
(mRNA), was explored by examining specific prostate cancer mutations and transcript 
signatures in EV subsets, and further evaluated for their possible utility in prostate cancer 
diagnosis. Next, the differences of prostate cancer and non-cancer derived EVs in cell-to-cell 
communication were examined, and the feasibility of autologous prostate cancer cell-derived 
EVs in the in vitro delivery of paclitaxel was tested. 
Literature review 
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The first work on EVs dates from the mid-1940s (Chargaff and West, 1946), with the 
discovery that platelet-free plasma contained a clotting factor that could be isolated by 
ultracentrifugation, which more than twenty years later was described as “platelet dust” 
(Wolf, 1967). Initial observations also included matrix "vesicles" identified during bone 
calcification (Anderson, 1969). Until the early 1980s, EV studies were mainly limited to the 
understanding of the cell function without considering soluble factors or molecules released 
to the extracellular medium. During the 1980s, another vesicular secretion pathway was 
suggested in which vesicles formed within multivesicular bodies (MVBs) were secreted to the 
extracellular space as a form of cellular waste release (Harding and Stahl, 1983; Pan and 
Johnstone, 1983). Indeed, the term “exosome” was first introduced when referring to 
membrane fragments isolated from biofluids (Trams et al., 1981), and proposed for vesicles of 
endosomal origin in the late-1980s (Johnstone et al., 1987).  
This early work inspired a new era of vesicle research prospering in the 2000s with EVs 
as a main focus. Our understanding of the relevance of EVs as multifunctional mediators of 
cell-to-cell communication has exponentially increased over the last decade and the EV field 
has rapidly expanded to explore the different areas where EVs may participate. Of special 
interest to the EV field is the marked relation of EVs to the different aspects of cancer 
development and their novel application as drug delivery vehicles. Figure 1 shows the 
evolution and the fast-growing interest in research focusing on the use of EVs in cancer 
biomarker discovery and drug delivery.  
 
 
 
Figure 1. Bar graphs showing the number of publications referring to the use of EVs in cancer 
biomarker and drug delivery. An advanced search was performed in the Web of Science (accessed 
16.01.17) to find, for each year, from 2000 to 2016, all articles in English with the terms “extracellular 
vesicles, ectosome(s), exosome(s), microvesicle(s), microparticle(s), apoptotic bod(ies), prostasome(s), 
oncosome(s)” and “cancer biomarker(s)” or “drug delivery”. The term microparticle(s) was excluded 
from the drug delivery search since it has a different meaning in pharmacological settings. The figure 
is intended to show the expansion of the use of EVs as cancer biomarkers and drug delivery vehicles. 
No comparison to other fields was made, since the number of publications was not normalized to the 
total number of scientific life-sciences publications per year. 
 
 
 The terminology used to refer to EV subpopulations is diverse and has previously 
been based on the EV size and cellular origin, or EV presence outside or inside the cells. The 
term EVs was proposed to encompass all types of membrane vesicles released into the 
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extracellular space, regardless of their differences in biogenesis and composition (György et 
al., 2011). However, there is no consensus in either terminology (Gould and Raposo, 2013) or 
EVs classification (Witwer et al., 2013), mainly because the present purification methods 
often result in mixtures of heterogeneous vesicle subsets. Despite the difficulty in isolating 
and characterizing EVs in a standardized manner, the general criteria classify EV 
subpopulations based on their biogenesis. Additional factors such as density, cellular origin, 
size, and cargo, have also been used to classify EVs (Colombo et al., 2014). In the following 
review of literature, different characteristics related to EV formation, composition, and 
functions are described.  
 
 
?????? ????????????????????????????????
The diversity, abundance, and molecular composition of EVs reflect not only the state 
and identity of their parent cells, but also the diversity of the biogenetic pathways (Théry et 
al., 2009). Currently, EVs are most often classified into three main categories based on their 
biogenesis: exosomes (EXOs), microvesicles (MVs), and apoptotic bodies (ABs). 
The biogenesis of EXOs is initiated by inward invagination of the cellular plasma 
membrane forming the early endosomes (Figure 2). While the early endosomes mature into 
late endosomes, the membrane undergoes a series of inward invaginations leading to the 
formation of ~40–100 nm intraluminal vesicles (ILVs) engulfing cytosolic components and 
incorporating peripheral and transmembrane proteins. The endosomal sorting complexes 
required for transport (ESCRT), including ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III, ALG-
2-interacting protein X (Alix), and tumor susceptibility 101 (TSG101), trigger the formation of 
ILVs in late endosomal multivesicular bodies (MVBs) (Huotari and Helenius, 2011; Hurley 
and Hanson, 2010; Raiborg and Stenmark, 2009; Thery et al., 2001). The MVBs can either be 
targeted for degradation in the lysosome by ubiquitin-dependent interactions with ESCRT-0, 
ESCRT-I, and ESCRT-II (Johnstone et al., 1987), or may fuse with the plasma membrane in 
an ubiquitin-independent manner, secreting the EXOs (Théry et al., 2002). Several proteins 
participate in this process, including Alix, a protein that interacts with ESCRT-III binding 
syntenin, providing a distinctive signature to avoid lysosomal degradation (Baietti et al., 
2012; Hurley and Odorizzi, 2012). Also, GTPases such as Rab5, Rab7 (Baietti et al., 2012; 
Vanlandingham and Ceresa, 2009), and Rab11 (Savina et al., 2002) regulate endocytic 
trafficking and cargo segregation, while Rab27 and Rab35 regulate the secretion of EXOs 
(Hsu et al., 2010). Other proteins involved in the EV biogenesis and trafficking of biological 
membranes include soluble NSF attachment protein receptors (SNAREs) (Chen and Scheller, 
2001), ADP-ribosylation factor 6 (ARF6) and its effector phospholipase D2 (Ghossoub et al., 
2014), and TSG101 and vacuolar protein sorting 4 (Bishop and Woodman, 2000; Buschow et 
al., 2005). The mechanisms and molecules that regulate the fusion of MVBs with the plasma 
membrane are not yet fully understood. The ESCRT machinery is considered to be mainly 
involved in sorting proteins destined for lysosomal degradation, whereas sorting cargo into 
the MVBs and EXOs is ubiquitin- and ESCRT- independent, and other molecules such as 
CD63 may participate in this process (van Niel et al., 2011). Alternatively, another ESCRT-
independent mechanism for EXO biogenesis dependent on the sphingolipid ceramide has 
been proposed (Trajkovic et al., 2008). Ceramide contributes to the inward budding of the 
plasma membrane generating another ILV population destined for secretion as EXOs 
(Trajkovic et al., 2008). However, the manner of cargo loading in the ceramide-dependent 
pathway is so far unknown. 
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Figure 2. Schematic representation of the biogenesis of the EV subpopulations. Exosome 
formation is initiated by endocytosis. The endocytic vesicles first mature to early endosomes, and then 
into late endosomes or multivesicular bodies (MVBs). After interaction with components from the 
endosomal sorting complex (ESCRT), via the ubiquitin dependent pathway, MVB constituents can be 
sorted to lysosome for degradation. In the ubiquitin-independent pathway, other components such as 
ESCRT-III, ALG-2-interacting protein X (Alix), and tumor susceptibility gene 101 (TSG101) are 
involved. If Alix binds to the MVB components, Rab proteins will intervene and the cargo will be 
released by the fusion of MVBs with the plasma membrane. Microvesicles are formed by outward 
budding, fission, and shedding of the plasma membrane. The process is regulated by the processing of 
cytoskeleton as well as lipid dynamics, including lipid rafts that promote membrane curvature. 
Apoptotic bodies are EVs of varying size generated during programmed cell death after nuclear 
condensation, cell shrinkage, and fragmentation. Other vesicles such as Golgi transport vesicles 
contribute to the vesicular secretome of cells, but these are not EVs.  
 
 
Outward budding or shedding and fission of the plasma membrane form blebs of 
varying size (100–1000 nm), termed MVs, which are released to the extracellular space 
(Théry et al., 2009) (Figure 2). During MV budding, lipid rafts including ceramide, 
regulatory proteins, and cytoskeleton elements, can promote membrane curvature and 
extensive cytoskeletal changes, promoting the formation of MVs (Bianco et al., 2009; 
McConnell and Tyska, 2007). Intracellular calcium changes and transporters are involved in 
the maintenance of membrane phospholipid asymmetry (Zwaal and Schroit, 1997), and so 
are likely involved in MV biogenesis (Piccin et al., 2007; Théry et al., 2009) although the 
regulatory mechanisms responsible for MV formation are still unknown. The formation of 
MVs has been speculated to share common features with the EXO biogenesis. For instance, 
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the ESCRT component TSG101 is known to interact with arrestin domain-containing protein 
1, leading to the evagination of the plasma membrane and release of MVs (Kuo and Freed, 
2012; Nabhan et al., 2012). Additionally, the interaction between actin-remodeling proteins 
such as the ARF6, and components of the Rho signaling pathway have been shown to 
participate in the MV formation (Li et al., 2012). Thus, the key molecules participating in the 
biogenesis of MVs and EXOs seem to be at least partially shared. Another category of EVs 
termed large oncosomes (LOs) was first described in relation to prostate cancer cells (Di 
Vizio et al., 2009). LOs are typically large EVs derived from cancer cells that have acquired a 
migratory and metastatic amoeboid phenotype. They usually range from 1-10 μm and contain 
oncogenic material (Minciacchi et al., 2015). The activation of protein kinase B (AKT) and 
epidermal growth factor receptor (EGFR) pathways, together with the silencing of the 
cytoskeletal regulator diaphanous related formin-3, promotes the release of LOs (Di Vizio et 
al., 2012; Di Vizio et al., 2009). Although MVs and LOs share some similarities, including the 
presence of molecules such as ARF6 involved in MV and LO biogenesis (Di Vizio et al., 2012; 
Muralidharan-Chari et al., 2009), it is not yet clear if LOs are a subtype of cancer-derived 
MVs or an entirely separate vesicle category. 
During programmed cell death, after nuclear condensation, cell shrinkage, and 
fragmentation, cells generate variable sized ABs. They range from 50–5,000 nm and are 
packed with fragmented nuclear and cytoplasmic components from the dying cell (György et 
al., 2011; Nawaz et al., 2014), which explains their heterogeneity with regard to content, size, 
and morphology (Figure 2). The actin-myosin system has been proposed as the contractile 
force that drives the blebbing, and the Rho effector protein ROCK1, which participates in the 
phosphorylation of myosin, contributes to the formation of membrane blebs and ABs 
(Coleman et al., 2001). Caspase proteases are also involved in the externalization of 
phosphatidylserine that acts as an “eat me” signal, mediating the recognition of ABs by 
phagocytic cells (Fadok et al., 1992; Martin et al., 1995). 
The complexity and overlap of pathways involved in EV biogenesis generates different 
explanations about the mechanisms involved in the formation and composition of EV 
subpopulations. However, while ABs are generated during programmed cell death, MVs and 
EXOs are formed from living cells during normal physiological and pathological processes.  
 
 
?????? ?????????????????????????????
EVs carry a wide variety of molecules as their cargo and partly resemble their parent 
cells (Théry et al., 2009). EVs are composed of a lipid bilayer enclosing membrane-associated 
and soluble proteins, nucleic acids, lipids, and other metabolites (Figure 3). The specific 
composition of EVs protects their internal cargo from enzymatic degradation, and thus 
preserves them as a source of biological information. Three databases, including EVpedia 
“evpedia.info” (Kim et al., 2015), Vesiclepedia “www.microvesicles.org” (Kalra et al., 
2012), and Exocarta “www.exocarta.org” (Mathivanan et al., 2012), contain information 
about the currently known components of EVs.  
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Figure 3. General representation of the EV composition. The molecular cargo of EVs consists of 
proteins, nucleic acids, lipids, and other metabolites. The EV composition widely varies based on the 
EV subpopulation and the cellular origin. The main subclasses of molecules identified in EVs based on 
their cellular location and function include: proteins e.g., adhesion or targeting molecules, enzymes, 
antigen presentation, signal transduction, cytoskeletal proteins, membrane trafficking, multivesicular 
bodies (MVB) biogenesis, and other cytosolic proteins; lipids e.g., ceramide, phosphatidylserine, 
glycosphingolipids, sphingomyelin, cholesterol; and nucleic acids e.g., DNAs, messenger RNAs 
(mRNAs), microRNAs (miRNAs), and other non-coding RNAs (ncRNAs). 
 
 
Due to the endosomal and plasma membrane origin of EVs, they display within their 
cargo features of ILVs, MVBs, and cellular plasma membrane. EVs are enriched in several 
protein components, some of them known as “common EV markers”. Tetraspanins such as 
CD63, CD9, CD81, CD82; membrane trafficking and lipid raft associated proteins such as 
annexin, flotillins, Rabs; and cytosolic proteins including heat shock proteins, TSG101, and 
Alix are some well-known examples of EV protein markers (Fevrier and Raposo, 2004; 
Mathivanan et al., 2010; Witwer et al., 2013; Zöller, 2009). Lipid-wise, EVs are known to be 
enriched in glycosphingolipids, sphingomyelin, cholesterol, phosphatidylserine, and 
ceramide compared to their parent cells (Llorente et al., 2013; Record et al., 2014; Trajkovic 
et al., 2008; Wubbolts et al., 2003). During the EV biogenesis, other metabolites such as 
sugars, nucleotides, amino acids, enzymatic cofactors, and regulatory molecules are also 
incorporated into the vesicles (Altadill et al., 2016; Mayr et al., 2009; Zhao et al., 2016), 
although only limited reports describing the metabolites present in different EVs are 
currently available. 
A major discovery in the EV field was the finding that functional RNA species, 
including mRNAs and microRNAs (miRNAs) were present in EVs, and that the EV-
associated RNA could be horizontally transferred to recipient cells and efficiently translated 
by them (Deregibus et al., 2007; Ratajczak et al., 2006; Valadi et al., 2007). Since these 
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discoveries, several other groups have identified RNA molecules in EVs isolated from cell 
cultures and biofluids (Quinn et al., 2015; Zhang et al., 2015a). It has also been shown by 
deep sequencing analysis that EVs contain additional non-coding RNAs molecules (ncRNAs) 
other than miRNAs. These RNA species include small interfering RNA (siRNA), vault RNA, 
transfer RNA, mitochondrial RNA, long non-coding RNA (lncRNA), Y RNA, piwi-interacting 
RNA, and small nucleolar RNA (Ahmed et al., 2014; Bellingham et al., 2012; Lunavat et al., 
2015; Nolte-'t Hoen et al., 2012; Vojtech et al., 2014). However, the transfer and effect of 
these RNAs on recipient cells has not been investigated. A more recent breakthrough finding 
was the discovery of DNA molecules in EVs isolated from cell culture supernatants and 
biofluids. Several DNA molecules including mitochondrial DNA (mtDNA) (Guescini et al., 
2010), single-stranded DNA (Balaj et al., 2011), and double-stranded DNA fragments (Cai et 
al., 2013; Waldenstrom et al., 2012) have been identified in various EVs.  
Based on the simultaneous biogenesis of several EV subpopulations, and the limited 
efficacy of the currently available isolation methods to obtain pure EV subsets, the exact 
composition and characteristics of MVs and EXOs are not yet fully understood. The majority 
of protein markers are conserved across EV subsets as demonstrated by several quantitative 
proteomic studies (Aatonen et al., 2014; Clark et al., 2015; Keerthikumar et al., 2015; Kowal 
et al., 2016; Minciacchi et al., 2015; Turiák et al., 2011; Xu et al., 2015). However, their 
composition also varies based on their source of origin and the down-stream isolation 
method. To date, no specific markers are available to distinguish EV subsets, and most of the 
literature classifying MVs and EXOs based on their specific markers can be misleading. A 
recent study proposed a new way of categorizing EVs that could be implemented to any 
source of vesicles isolated from cell culture supernatants or biological fluids (Kowal et al., 
2016). Based on the presence of protein markers, EVs can be classified as a) large EVs 
pelleted at low speeds, b) medium-sized EVs pelleted at intermediate speeds, and c) small 
EVs pelleted at high speeds. Among the small EVs, four subcategories emerged including: c1) 
small EVs co-enriched in CD63, CD9, and CD81 and endosomal markers; c2) small EVs 
devoid of CD63 and CD81, but enriched in CD9 and associated with endocytic and plasma 
membrane markers; c3) small EVs devoid of CD63, CD9, and CD81 not associated with 
endosomal signature; and c4) small EVs enriched in extracellular matrix proteins or serum-
derived factors in the absence of endosomal signatures (Kowal et al., 2016). 
 
 
?????? ???????????????????????????????????????????????
Cell-to-cell communication is a key regulator of many biological and pathological 
processes. Cells communicate by secreting signaling molecules such as hormones, cytokines, 
growth factors, lipid mediators, and neurotransmitters that locally or remotely activate the 
target cells, inducing a broad range of responses. Part of the cellular secretome includes a 
heterogeneous mixture of EVs, which actively participate in the intercellular communication 
process. When EVs are released into the extracellular space, they can be eliminated from the 
body by secretion into biofluids e.g., urine, or be internalized by cells delivering their cargo 
and influencing the recipient’s cells. The transfer of functional RNA species and proteins 
(Alvarez-Erviti et al., 2011; Montecalvo et al., 2012; Ratajczak et al., 2006; Valadi et al., 2007) 
was a concrete proof that EVs can effectively deliver their cargo to recipient cells. The 
induction of luciferase activity by luciferin-loaded EVs in luciferase transfected dendritic cells 
clearly supported the intercellular delivery of the EV cargo (Montecalvo et al., 2012). 
Additionally, the use of fluorescent membrane dyes e.g., PKH67, DiD, DiL; GFP-tagged EV 
proteins e.g., GFP-CD63; or fluorescent protein dyes e.g., carboxyfluorescein succinimidyl 
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ester (CFSE) and CFDA-SE, coupled with confocal microscopy has permitted a direct 
visualization of EV internalization and co-localization studies within cell organelles 
(Escrevente et al., 2011; Feng et al., 2010; Lai et al., 2015; Svensson et al., 2013; Tian et al., 
2010). However, given the resolution limits of the current microscopes, the ability to detected 
single vesicles from clusters of EVs is still challenging. 
The mechanisms by which EVs and their cargo are delivered into the cells have been 
subjected to continuous debate. EVs may become incorporated into the cells as a 
consequence of the continuous endocytosis of the cell membrane (Mulcahy et al., 2014). 
However, the specific protein contents of EVs such as tetraspanins, integrins, and 
immunoglobulins indicate an active EV internalization process that requires specialized 
interactions between EVs and cells. Currently, several mechanisms for EV uptake have been 
postulated and are discussed (Mulcahy et al., 2014). Briefly, EVs can either fuse with the 
cellular plasma membrane to deliver their cargo (Del Conde et al., 2005; Parolini et al., 
2009), or be internalized by the cells as intact EVs. There is also evidence for alternative EV 
internalization mechanisms: energy-dependent receptor-mediated endocytosis, including 
clathrin-mediated endocytosis and caveolin-mediated endocytosis (Escrevente et al., 2011; 
Nanbo et al., 2013; Svensson et al., 2013), macropinocytosis (Fitzner et al., 2011; Tian et al., 
2014b), and phagocytosis (Feng et al., 2010). However, the EV internalization process likely 
occurs via multiple mechanisms, and thus the existence of different internalization routes 
could reflect the simultaneous activation of uptake pathways based on the origin or the 
subpopulation of the EVs being internalized. Moreover, the degree to which some of these 
pathways represent EV clearing mechanisms rather than promoting cellular responses is far 
from clear. Although the responses caused by RNA molecules require EV internalization, 
phenotypic changes in recipient cells may be caused by receptor-ligand interactions without 
the need of EV uptake (Mulcahy et al., 2014). Indeed, the specificity between protein-to-
protein interactions is likely what drives EV targeting to certain tissues (Hoshino et al., 2015; 
Svensson et al., 2013), although the exact mechanisms remain elusive. 
 
 
?????? ????????????????????????????????????????????????
The specific physiological and pathological properties of EVs depend on the origin and 
characteristics of their parent cells (Kalluri, 2016; Théry et al., 2009). While recent research 
focuses on elucidating the roles of EVs in intercellular communication, the EV-mediated 
maintenance of homeostasis and regulation of physiological functions remains less explored. 
In healthy individuals, EVs participate in the regulation and maintenance of embryonic 
development, reproduction, coagulation, cell death, inflammation, angiogenesis, tissue 
repair, or act as immune modulators with either immune-activating or immune-suppressive 
effects (Yáñez-Mó, Siljander et al., 2015). On the other hand, in pathological settings such as 
cancer, EVs can contribute in major disease-related functions including epithelial-to-
mesenchymal transition, inhibition of cell death, invasion, metastasis, tumor proliferation, 
stimulation of angiogenesis, immunosuppression, and eventually pre-metastatic niche 
formation (An et al., 2015; Azmi et al., 2013; Nawaz et al., 2014; Rak, 2013). Additionally, 
EVs actively participate in other pathologies such as viral and prion transmission (Nguyen et 
al., 2003; Pegtel et al., 2010). This review of literature will focus on the description of the 
potential role of EVs in cancer. 
 
Literature review 
 
 9  
 
???? ??????????????
?????? ??????????????????????? ????????????????????????
Intercellular communication is increasingly distorted during tumor progression and 
several studies suggested that EVs are supportive of this process. Cancer-derived EVs can 
facilitate the intercellular exchange of bioactive cancer-related molecules contributing to the 
acquisition of the different hallmarks of cancer described by Hanahan and Weinberg 
(Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). As summarized below and 
recently reviewed (Kanada et al., 2016; Meehan and Vella, 2016), there is now overwhelming 
evidences showing the participation of different cancer-derived EVs in the functional transfer 
of nucleic acids, proteins, and lipids to target cells promoting tumorigenesis. EVs enable 
cancer cell progression by, for instance, sustaining proliferative signaling, resisting cell death, 
promoting angiogenesis, increasing invasion and metastasis, and evading clearance by the 
immune system (Figure 4). Below, the currently available literature for the contribution of 
EVs to the acquisition of hallmark capabilities of cancer is reviewed. 
 
 
Figure 4. Schematic representation of the hallmarks of cancer acquired during tumor 
progression as described by Hanahan and Weinberg, Cell, 2011. The hallmark functions of cancer 
where EV participation has been shown are marked in blue, including sustaining proliferative 
signaling, resisting cell death, promoting angiogenesis, activating invasion and metastasis, and 
evading immune surveillance. The functions marked in yellow are those where the role of EVs is poorly 
understood, including evading growth suppressors, reprogramming cell metabolism, tumor-promoting 
inflammation, and inducing genomic instability. The participation of EVs enabling replicative 
immortality, marked in red, has not been so far reported. 
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Sustaining proliferative signaling 
Cancer-derived EVs transfer proliferative signals to recipient cells contributing to their 
malignization by enhancing cellular growth and proliferation. EVs can participate in the 
activation of signaling pathways that are commonly dysregulated in cancer. For instance, 
cancer-derived EVs from glioma, gastric, prostate, bladder, and lung origin, participated in 
the activation of the phosphatidylinositide 3-kinases/AKT and/or MAPK/extracellular signal-
regulated kinases pathways (Al-Nedawi et al., 2008; Choi et al., 2014; Qu et al., 2009; Yang 
et al., 2013). In addition, somatic mutations in cancer cells can activate down-stream 
signaling promoting tumor growth. The intercellular transference of the oncogenic form of 
EGFRvIII to cells lacking the isoform via glioma-derived EVs led to an increase in 
proliferation and survival of the glioma cells (Al-Nedawi et al., 2008). Similarly, the transfer 
of mutant KRAS-containing EVs to cells expressing only wild-type KRAS enhanced their 
cellular growth (Demory Beckler et al., 2013). In addition to oncogenic sequences, 
phosphorylated proteins, mRNAs, and miRNAs can also be transferred via EVs contributing 
to the progression of the tumors (Soldevilla et al., 2014; Yang et al., 2016). For example, EVs 
isolated from neuroblastoma, nasopharyngeal carcinoma, and thyroid cancer contained over-
expressed levels of miRNAs that regulated cell proliferation and differentiation (Haug et al., 
2015; Lee et al., 2015a; Ye et al., 2014). The transfer of EV-associated ΔNp73 mRNA to colon 
cancer cells has also been shown to provide proliferation potential and chemoresistance 
(Soldevilla et al., 2014). 
 
Resisting cell death  
Apoptosis-mediated programmed cell death is usually attenuated in certain tumor cells 
promoting tumorigenesis, and triggered in different cancer cells during tumor development 
or in response to therapy. Cancer-derived EVs have both direct and indirect roles in cell 
death. They have been implicated in the transfer of anti-apoptotic factors between cells, such 
as B-cell lymphoma (Bcl)-extra large, anchorage-independent growth and survival factors 
(Al-Nedawi et al., 2008; Antonyak et al., 2011). In contrast, EVs derived from gastric and 
bladder cancer cells were shown to suppress apoptosis by incrementing the expression of Bcl-
2 and cyclin-D1, and reducing the levels of Bax and caspase-3 (Koga et al., 2005; Qu et al., 
2009; Yang et al., 2013). Many different types of human cancers resulted in mutated or 
missing gene for tumor protein p53 (TP53), which then enabled resistance to apoptosis 
(Meek, 2009). Interestingly, TP53 mutations have been detected in EVs isolated from cancer 
patients, harboring the same TP53 mutations as the primary tumors (Kahlert et al., 2014; 
Thakur et al., 2014). However, how EVs are mechanistically involved in resisting cell death is 
not yet well understood. 
 
Promoting Angiogenesis 
The formation of new blood vessels is an essential requirement for tumor development 
and progression. EVs are active modulators of angiogenesis and endothelial cell activation, 
contributing to the formation of blood vessels within the tumors (Bian et al., 2014). EVs 
derived from platelets, leukocytes, and endothelial progenitor cells, have been shown to 
deliver pro-angiogenic factors and functional mRNAs promoting neo-angiogenesis both in 
vivo and in vitro (Deregibus et al., 2007; Rhee et al., 2004). Cancer-derived EVs expressing 
the tetraspanin Tspan8 were shown to promote angiogenic functions (Gesierich et al., 2006), 
in support of tumor growth, by elevating the levels of vascular endothelial growth factor 
(VEGF) and VEGR receptor 2 (Nazarenko et al., 2010). In the absence of pro-angiogenic 
signals, melanoma-derived EVs were also shown to promote tubule branching by modifying 
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the morphology of the endothelial tubule network (Hood et al., 2009). The increased vessel 
density and branching by the delivery of delta-like 4 has been reported in colorectal 
carcinoma (Jubb et al., 2009) and glioma-derived EVs (Sheldon et al., 2010). In line with 
those findings, cancer-derived EVs harboring the oncogenic form of EGFRvIII induced the 
activation of MAPK and AKT signaling pathways, which stimulated a complex angiogenic 
mechanism including the production of VEGF and signaling activation of VEGFR receptor 2 
(Al-Nedawi et al., 2008; Al-Nedawi et al., 2009). Hypoxia is also closely related to tumor 
progression and aggressiveness, and it has been shown to promote the release of EVs by 
prostate, breast, glioma, and leukemic cells (King et al., 2012; Kucharzewska et al., 2013; 
Ramteke et al., 2015; Tadokoro et al., 2013). EV proteins and mRNAs derived from hypoxic 
glioblastoma cells and patient plasma were able to trigger angiogenesis and tumor growth 
(Kucharzewska et al., 2013; Skog et al., 2008). EVs can also promote angiogenesis with 
microRNAs (miR-214, miR-210) (Tadokoro et al., 2013; van Balkom et al., 2013), activate 
angiogenesis and suppress senescence (miR-92a) (Umezu et al., 2013), and also enhance cell 
migration, tube formation, and increase angiogenesis by targeting a factor that inhibits the 
hypoxia inducible factor-1 (HIF1) pathway (miR-135b) (Umezu et al., 2014). However, the 
molecular crosstalk during tumor development between hypoxic cells and EVs is only just 
been realized, and in vivo studies are required to discover the mechanisms used by hypoxic 
cells to communicate through EVs.  
 
Activating invasion and metastasis 
The crosstalk between the stroma- and cancer-derived EVs is relevant in tumor 
proliferation, and many studies are focusing on elucidating the role of EVs as mediators of 
cell invasion and metastases. EVs contribute to the epithelial-to-mesenchymal transition by 
the transference of EV-associated HIF1α (Aga et al., 2014) and miR-200 (Le et al., 2014). 
Significantly, EV-associated transforming growth factor beta (TGF-β) could trigger the 
differentiation of fibroblasts into myofibroblasts as characterized by the de novo expression 
of α-smooth muscle actin (Webber et al., 2015; Webber et al., 2010). Both stromal and 
mesenchymal cells secrete EVs with tumor promoting effects (Roccaro et al., 2013; Zhu et al., 
2012). EVs secreted from cancer-associated fibroblasts (CAFs) have been shown to promote 
the migration and motility of breast cancer cells through Wnt-planar cell polarity signaling 
(Luga et al., 2012), and also the activation of key oncogenic pathways such as Notch and 
RhoA in cancer cells (Shimoda et al., 2014). In that line, EVs generated under hypoxic 
conditions were shown to promote invasiveness and stemness of prostate cancer cells, and 
the stimulation of a CAF phenotype in prostate stromal cells (Ramteke et al., 2015). 
Additionally, oncogenic protein tyrosine kinase- containing EVs increased gastrointestinal 
stromal tumor invasiveness (Atay et al., 2014). Similarly, mutant K-ras and H-ras and/or 
Rab proteins in cancer-derived EVs contributed to prostate cancer progression by neoplastic 
transformation of the phenotype of adipose-derived stem cells (Abd Elmageed et al., 2014). 
EVs actively participate in the formation of the pre-metastatic niche, which is another 
fundamental phenomenon in the development of cancer. Firstly, melanoma-derived EVs 
have been shown to prepare sentinel lymph nodes for tumor metastasis (Hood et al., 2011). 
Metastatic melanoma-derived EVs were shown to reprogram bone marrow progenitor cells 
via the hepatocyte growth factor receptor, stimulating vasculogenic and pro-metastatic 
behavior (Peinado et al., 2012). Likewise, pancreatic cancer-derived EVs also participated in 
the preparation of the metastatic niche in liver (Costa-Silva et al., 2015). The presence of 
macrophage migration inhibitory factor in EVs induced the secretion of fibronectin by 
hepatic stellate cells and TGF-β production in liver Kupffer cells, contributing to the 
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remodeling of the extracellular matrix and promoting the metastatic niche formation (Costa-
Silva et al., 2015). Additionally, several miRNAs within the EVs have been shown to influence 
the early phases of the niche formation; for instance, the transfer miRNAs such as miR-19a 
from brain astrocytes to cancer cells down-regulated the expression of phosphatase and 
tensin homolog (PTEN), which facilitated the proliferation of metastatic brain cells (Zhang et 
al., 2015b). Also, miR-122 in breast cancer-derived EVs reprogrammed the glucose 
metabolism, resulting in the suppression of glucose intake by normal cells and increased 
nutrient availability to cancer cells in support of metastasis (Fong et al., 2015). Likewise, EV-
associated miR-200 showed altered gene expression and induction of local and distant breast 
cancer metastasis (Le et al., 2014). EV-derived miRNAs were also shown to regulate tight 
junction proteins; for instance, metastatic breast cancer cell-derived EVs secreted miR-105 
thereby suppressing the expression of tight junction 1 protein in endothelial cells (Zhou et al., 
2014). In addition, EVs derived from the metastatic brain cells carrying miR-181c were 
capable of disrupting tight junction proteins, contributing to cell extravasation and vessel 
leakiness, and promoting metastasis to brain and liver (Tominaga et al., 2015).  
EV-regulation was recently reported to be involved in cell movement, with EVs coated 
with fibronectin-integrin complexes as critical motility-promoting cargo (Sung et al., 2015). 
Importantly, the specific integrin expression patterns in EVs may predetermine induction of 
organ-specific metastasis (Hoshino et al., 2015). However, it is possible that EVs alone 
cannot promote the metastatic niche formation, and due to the tumor complexity, other 
biomolecules from the tumor secretome are likely required to trigger this process (Bobrie et 
al., 2012; Jung et al., 2009). 
 
Evading immune surveillance 
Cancer cells must escape the immune system to survive and metastasize. Cancer cells 
have developed numerous mechanisms to evade the immune system in which EVs 
participate, although the contribution of EVs to the evasion of the immune surveillance and 
tumor immunoediting is not yet well understood. Cancer-derived EVs influence the immune 
evasion responses without direct interaction with immune cells, for instance by suppressing 
the anti-tumor T cell responses (Abusamra et al., 2005; Clayton et al., 2007; Huber et al., 
2005; Taylor and Gercel-Taylor, 2005). EVs containing pro-apoptotic molecules, such as Fas-
ligand and tumor necrosis factor-related apoptosis-inducing ligand, induce apoptosis of 
activated tumor-specific T cells inhibiting their cytotoxic effect towards the target tumor 
(Andreola et al., 2002; Kim et al., 2005). Cancer-derived EVs also induce immune 
suppression by promoting regulatory T cell expansion thereby contributing to the tumor 
escape from the immune system (Whiteside, 2005). Moreover, melanoma- and colorectal 
carcinoma-derived EVs inhibited monocyte differentiation towards dendritic cells by 
inducing the secretion of TGF-β (Valenti et al., 2006). Another immunosuppressive 
molecule, adenosine, present in tumor-derived EVs co-expressing CD39 and CD73, 
negatively regulated the local immune response by inhibiting T cell activation (Clayton et al., 
2011). Lymphocyte cytotoxic functions were also impaired by circulating EVs in prostate 
cancer patients, promoting tumor escape (Lundholm et al., 2014). Additionally, EV-
associated miRNAs such as let-7 and miR-155 were suggested to mediate the evasion of the 
immune response by regulating T-cell responses (Okoye et al., 2014). 
 
Evading growth suppressors 
To maintain tissue homeostasis, it is fundamentally important to eliminate any 
malfunctioning cells in the organism. Despite the clear evidence that cancer-derived EVs 
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sustain proliferative signals in cancer cells, the mechanisms of the evasion of cell growth 
suppression via EVs remains poorly understood, and only a few studies have assessed the 
effect of EVs evading growth suppressors. EVs have been suggested to harbor miRNAs with 
tumor suppressor targets, including miR-143, which can reduce the growth of prostate cancer 
cells (Kosaka et al., 2012) and miR-23b, which has been shown to reduce angiogenesis, 
invasion, and metastasis of bladder (Ostenfeld et al., 2014) and breast cancer cells (Ono et al., 
2014). 
 
Reprogramming cell metabolism 
The acidification of the microenvironment during tumor formation occurs due to the 
up-regulation of the glycolytic pathway under hypoxic conditions. The acidic pH of tumors is 
essential for enhanced EV secretion and trafficking (Parolini et al., 2009). In addition, the 
secretion of HIFs can control EV formation in breast cancer cells (King et al., 2012), 
facilitating the acquisition of malignant properties by the cancer cells (Wang et al., 2014c). 
An outstanding study has recently demonstrated that CAF-derived EVs can reprogram the 
metabolic machinery of cancer cells by inhibiting mitochondrial oxidative phosphorylation, 
thereby increasing glycolysis and glutamine-dependent reductive carboxylation (Zhao et al., 
2016). Hence, changes in the metabolic microenvironment of the tumor modulate 
intercellular communication via EVs, though the mechanisms are currently poorly 
understood. 
 
Tumor-promoting inflammation  
Cancer-associated inflammation responses usually involve the dysregulated activity of 
different immune cells. EVs have been reported to stimulate chronic inflammation by 
reducing the innate immune responses (Buzas et al., 2014; Fabbri et al., 2012). EVs can 
contribute to inflammation by carrying autoantigens, including heat-shock proteins, 
histones, α-enolase (Turiák et al., 2011); cytokines such as interleukin (IL)-1β (Boilard et al., 
2010; Pizzirani et al., 2007), IL-18, (Gulinelli et al., 2012) and IL-8 (Baj-Krzyworzeka et al., 
2011); lipid mediators (Barry et al., 1997; Esser et al., 2010); matrix metalloproteinases 
(Shimoda and Khokha, 2013); damage-associated molecular patterns including high mobility 
group protein B1 and S100 (Goh and Midwood, 2012; Schiller et al., 2013); and miRNAs such 
as let-7, miRNA-21, and miR-29a (Lehmann et al., 2012; Ohshima et al., 2010), some of 
which are ligands/activators of Toll-like receptors, such as toll-like receptor 7 (Ohshima et 
al., 2010). Despite the clear association of EVs and inflammation, the biological relevance 
during cancer progression has not yet been proven. 
 
Inducing genomic instability 
The role of EVs in prompting sustained genomic instability is currently unclear. It is 
also unknown whether the effect of EVs in the transformed cellular state is transient, 
permanent, or dependent on constant EV stimulation. A unique aspect of cancer EVs is that 
they contain activated oncoproteins, oncogenic DNA sequences, and oncomiRs that can be 
transferred between cells whereupon they prompt functional effects across cellular 
boundaries (Rak, 2013). Different oncogenic molecules such as EGFR, Ras, Myc, LMP1, 
SV40 large T, and latent membrane protein 1, have been identified in various types of EVs 
(Al-Nedawi et al., 2008; Balaj et al., 2011; Bergsmedh et al., 2001; Demory Beckler et al., 
2013; Meckes et al., 2010; Skog et al., 2008). For instance, the internalization of ABs 
containing H-ras, Myc or SV40 large T caused a manifest tumorigenic conversion of 
immortalized fibroblast (Bergsmedh et al., 2001). Likewise, fibroblasts exposed to the EV-
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mediated transfer of cancer-cell derived fibronectin and tissue transglutaminase showed 
permanent changes driving in vivo tumor cell growth (Antonyak et al., 2011). However, the 
intercellular transfer of oncogenic EVs containing mutant H-ras exerted transient regulatory 
effects that were unable to trigger a tumorigenic transformation in recipient cells (Lee et al., 
2016). The transfer of oncogenes by EVs could support the notion that EVs might promote 
potent but transient effects in cancer promoting genomic instability, even though the exact 
mechanisms are yet to be discovered. 
 
 
?????? ??????????????????????????????????????
A major challenge of the cancer research field is the discovery of biomarkers with 
relevant diagnostic and prognostic value. Ideally, a good biomarker should be efficient, 
detecting the disease before it develops or at an early stage, and specific for each cancer type. 
A biomarker should also contribute to monitoring the disease progression and be informative 
of the response to a treatment (Schork, 2015). The analysis of cancer-derived EVs has opened 
new insights in the biomarker discovery field. Cancer cells usually display an altered 
vesiculation in comparison with normal cells, releasing more EVs into the biofluids (Al-
Nedawi et al., 2008; Graves et al., 2004; Taylor and Gercel-Taylor, 2008). Additionally, EVs 
contain biomolecules within their cargo that reflect the content and pathological state of the 
parent cells, providing an enriched source of information (Kalluri, 2016). Because these 
molecules are contained within the EV membranes, they are also protected from degradation 
during transit. A number of these molecules, especially the EV-associated membrane 
proteins and nucleic acids, seem to show promise in cancer diagnosis and prognosis.  
Currently, the majority of studies relate to the role of EV-associated RNAs as a possible 
source of biomarkers, with special emphasis in miRNAs (Yokoi et al., 2015). Circulatory 
miRNAs have shown remarkable stability in plasma and serum (Mitchell et al., 2008), and 
they have been reported to be enriched in EVs (Gallo et al., 2012). However, many studies do 
not adequately report if the identified miRNAs were EV-associated or not. Similarly, mRNAs 
have also been identified in cancer-derived EVs, but only a few studies have so far addressed 
the possible clinical relevance of mRNA molecules in EVs. A comprehensive summary of the 
RNA species found in cancer-derived EVs isolated from biofluids is presented in Table I. 
 
 
Table I. EV-associated RNAs for diagnosis and prognosis of cancer. 
???????????? ????????? ????????? ??????????
Acute Leukemia miR-92 plasma (Tanaka et al., 2009) 
Bladder LASS2, GALNT1 mRNAs (present) 
ARHGEF39, FOX3 mRNAs (absent) 
urine (Perez et al., 2014) 
Breast 
miR-16, miR-1246, miR-451, miR-720 
plasma, milk, 
ductal fluids (Pigati et al., 2010) 
 miR-101, miR-372, miR-373 serum (Eichelser et al., 2014) 
Cervical 
miR-21, miR-146a 
cervicovaginal 
lavage (Liu et al., 2014) 
Colorectal let-7a, miR-1229, miR-1246, miR-150, 
miR-21, miR-223, and miR-23a 
serum (Ogata-Kawata et al., 
2014) 
 miR-17-92a cluster  (Matsumura et al., 2015) 
Esophageal miR-21 serum (Tanaka et al., 2013) 
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 miR-1246  (Takeshita et al., 2013) 
Gastric LINC00152 plasma (Li et al., 2015) 
 MAGE-1, HER-2/neu mRNAs  (Baran et al., 2010) 
 miR-21, miR-1225-5p peritoneal lavage (Tokuhisa et al., 2015) 
Glioblastoma miR-21 cerebrospinal fluid (Akers et al., 2013)  
 RNU6-1, miR-320, miR-574-3p serum (Manterola et al., 2014) 
 miR-21  (Mao et al., 2014) 
 EGFRvIII mRNA  (Skog et al., 2008) 
Glioma IDH1 mRNA cerebrospinal fluid 
(Chen et al., 2013; Wang 
et al., 2014b) 
Hepatocellular miR-21 serum (Wang et al., 2014b) 
 miR-718  (Sugimachi et al., 2015) 
Laryngeal  HOTAIR, miR-21 serum (Wang et al., 2014a) 
Lung  miR-17-3p, miR-21, miR-106a, miR-146, 
miR-155, miR-191, miR-192, miR-203, 
miR-205, miR-210, miR-212, miR-214 
plasma 
(Rabinowits et al., 2009) 
 let-7f, miR-30e-3p  (Silva et al., 2011) 
 miR-151a-5p, miR-30a-3p, miR-200b-5p,  
miR-629, miR-100 and miR-154-3p (Cazzoli et al., 2013) 
 let-7f, miR-30e-3p, miR-223, miR-301  (Rodríguez et al., 2014) 
 miR-486, miR-30d, miR-1, miR-499 serum (Hu et al., 2010) 
 miR-21 and miR-155  (Munagala et al., 2016) 
Melanoma miR-17, miR-19a, miR-21, miR-126, 
miR-149 
plasma 
(Pfeffer et al., 2015) 
Nasopharyngeal miR-24-3p, miR-891a, miR-106a-5p, 
miR-20a-5p, miR-1908 
serum 
(Ye et al., 2014) 
Ovarian cancer miR-21, miR-141, miR-200a, miR-200c, 
miR-200b, miR-203, miR-205 and miR-
214 
serum 
(Taylor and Gercel-
Taylor, 2008) 
Pancreatic miR-21, miR-17-5p serum (Que et al., 2013) 
 miR-1246, miR-4644, miR-3976,  
miR-4306 
 
(Madhavan et al., 2015) 
 APBB1IP, ASPN, Daf2, FoxP1, Bco31781, 
Gng2 mRNAs 
saliva 
(Lau et al., 2013) 
Prostate  
miR-141 
serum 
(Mitchell et al., 2008) 
 
miR-107, miR-141, miR-375, miR-574-3p 
serum/plasma 
(Bryant et al., 2012) 
 miR-1290, miR-375 plasma (Huang et al., 2015) 
 LncRNA-p21  (Işın et al., 2015) 
 PCA-3, TMPRSS2 mRNAs urine (Dijkstra et al., 2014; Nilsson et al., 2009) 
 AGR2 mRNA  (Neeb et al., 2014) 
 CDH3 mRNA  (Royo et al., 2016) 
 ERG, PCA-3, SPDEF mRNAs  (McKiernan et al., 2016) 
 
LASS2: ceramide synthase 2; GALNT1: polypeptide N-acetylgalactosaminyltransferase 1; ARHGEF39: rho 
guanine nucleotide exchange factor 39; FOX3: RNA binding protein, fox-1 homolog 3; LINC00152: long non-
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coding RNA Linc00152; MAGE-1: melanoma-associated antigen 1; HER-2/neu: human epidermal growth factor 
proto-oncogene neu; RNU6-1: RNA u6 small nuclear 1; EGFRvIII: epidermal growth factor receptor variant 3; 
IDH1: isocitrate dehydrogenase 1; HOTAIR: long-noncoding RNA; APBB1IP: Amyloid beta A4 precursor protein-
binding family B member 1-interacting protein; ASPN: asporin; Daf-2: insulin-like receptor precursor in C 
elegans; FoxP1: forkhead box P1; Gng2: G protein subunit gamma 2; PCA-3: prostate cancer antigen-3; TMPRSS2: 
transmembrane protease serine 2; AGR2: anterior gradient 2; CDH3: cadherin 3; ERG: V-Ets avian 
erythroblastosis virus E26 oncogene homolog; SPDEF: SAM pointed domain containing Ets transcription factor. 
 
 
In addition to RNA, EV-associated DNA may also hold prospective value for diagnostic 
purposes, since it can provide information about specific mutations present in the original 
tumors. DNA molecules exist in many different forms, including histone/DNA complexes or 
nucleosomes, EV-associated DNA, and virtosomes. These DNA forms can also be classified as 
circulating DNA, circulating-free DNA, cell-free DNA, and EV-DNA (Peters and Pretorius, 
2011). In contrast to RNA, the presence of DNA in EVs have been much less studied.  
In recent years, studies have focused on the EV-associated membrane proteins, since 
they may also serve as relevant EV-related diagnostic targets (Yokoi A et al., 2015). 
Particularly, cancer-derived EVs can be isolated using membrane specific proteins from 
cancer tissues. A comprehensive summary of the membrane proteins found in cancer-derived 
EVs isolated from biofluids is presented in Table II. 
 
 
Table II. EV-associated proteins for diagnosis and prognosis of cancer. 
 
???????????? ????????? ????????? ??????????
Acute leukemia CD34 plasma (Hong et al., 2014) 
Bladder EPS812, mucin-4 urine (Smalley et al., 2008) 
 EDIL-3/Del1  (Beckham et al., 2014) 
Breast Fibronectin plasma (Moon et al., 2016) 
 Periostin  (Vardaki et al., 2016) 
 Glypican-1 serum (Melo et al., 2015) 
Colorectal Claudin-3 ascites (Choi et al., 2011) 
 CD147, CD9 serum (Yoshioka et al., 2014) 
Gastric  CCR6, HER-2/neu, CD147, MAGE-1, 
C-MET 
serum 
(Baran et al., 2010) 
Glioblastoma EGFRvIII serum (Skog et al., 2008) 
Lung LRG1 urine (Li et al., 2011) 
 EGFR serum (Yamashita et al., 2013) 
 
SNX25, BTG1, PEDF, thrombospondin 
pleural 
effusion (Bard et al., 2004) 
Melanoma Caveolin-1, CD63 plasma (Logozzi et al., 2009) 
 TYRP2, VLA-4, Hsp70, MET  (Peinado et al., 2012) 
Nasopharyngeal  Galectin-9 serum (Klibi et al., 2009) 
Ovarian  MMP2, MMP9, uPA ascites (Graves et al., 2004) 
 CD24, EpCAM  (Runz et al., 2007) 
 EpCAM serum (Taylor and Gercel-Taylor, 2008) 
 L1CAM, CD24,  
ADAM10, CD147 (Keller et al., 2009) 
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 Claudin-4 plasma (Li et al., 2009) 
 TGFβ-1, MAGE3/6 (Szajnik et al., 2013) 
Pancreatic  EGFR plasma (Arscott and Camphausen, 2011) 
 Glypican-1 serum (Melo et al., 2015) 
Prostate PSA, PSMA urine (Mitchell et al., 2009; Overbye et al., 2015) 
 δ-catenin, caveolin-1, CD59 (Lu et al., 2009) 
 ITGA3, ITGB1 (Bijnsdorp et al., 2013) 
 TM256/C17orf61, LAMTOR1, ADIRF, 
TGM4, TMPRSS (Overbye et al., 2015) 
 CYP17A serum (Locke et al., 2009) 
 Survivin plasma (Khan et al., 2011; Khan et al., 2012) 
 PTEN  (Gabriel et al., 2013) 
 PSA  (Gabriel et al., 2013) 
 PSMA  (Mizutani et al., 2014; Park et al., 2016) 
Renal carcinoma MMP-9, DKP4, CD147, PODXL urine (Raimondo et al., 2013) 
 
EDIL-3/Del1: epidermal growth factor like repeats and discoidin domains 3; CCR6: chemokine receptor 6; 
HER-2/neu: human epidermal growth factor proto-oncogene neu; MAGE-1: melanoma-associated antigen 1; C-
MET: hepatocyte growth factor receptor; LRG1: leucine rich α2-glycoprotein 1; EGFR: epidermal growth factor 
receptor; SNX25: sorting nexin 25; BTG1: B-cell translocation gene 1; PEDF: pigment epithelium-derived factor; 
TYRP2: tyrosinase-related protein 2; VLA-4: very late antigen 4; Hsp-70: heat shock protein 70; MET: met proto-
oncogene tyrosine kinase; LRG1: leucine-rich α2-glycoprotein; EGFRvIII: epidermal growth factor receptor 
variant III; MMP2:?matrix metalloproteinase-2; MMp9: matrix metalloproteinase-9; uPA: plasminogen activator, 
urokinase; EpCAM: epithelial cell adhesion molecule; L1CAM: l1 cell adhesion molecule; ADAM10: a disintegrin 
and metalloproteinase domain 10; TGFβ-1: transforming growth factor beta 1; PSA: prostate-specific antigen; 
PSMA: prostate-specific membrane antigen; ITGA3: α3-integrin; ITGB1: ß1-integrin; TMEM265: transmembrane 
protein 256; LAMTOR1: late endosomal/lysosomal adaptor, MAPK and MTOR activator 1; ADIRF: adipogenesis 
regulatory factor; TGM4: transglutaminase 4; TMPRSS: transmembrane protease serine 2; CYP17A:?cytochrome 
P450 17A1; PTEN: phosphatase and tensin homolog. MMP-9: matrix metallopeptidase 9; DKP4: dickkopf related 
protein 4; PODXL: podocalyxin like. 
 
 
???? ????????????????
?????? ????????????????????????????????
Prostate cancer is the second most commonly diagnosed cancer in men worldwide and 
accounts for 30.6% of all male cancers in Finnish men between the years 2010 and 2014 
(Engholm et al., 2016). The probability of developing prostate cancer during a man´s lifetime 
is 15% (Siegel et al., 2015). Although prostate cancer has been extensively studied, so far 
there are only a few clinically used diagnostic and prognostic markers available. The 
heterogeneity of the tumors together with the variable clinical evolution of the patients, has 
led to a non-consensus of the causes behind prostate cancer progression (Tomlins et al., 
2006). Currently, the most commonly used prognostic prostate cancer markers include the 
prostate-specific antigen (PSA), Gleason score, and clinical tumor stage (Catalona et al., 1991; 
Gittes, 1991; Gleason, 1966; Gleason and Mellinger, 1974; McNeal et al., 1986; Mellinger et 
al., 1967; Stamey et al., 1987). Thus, when prostate cancer is suspected due to elevated PSA 
levels in blood (4.0 ng/mL is the cut-off level for recommending a biopsy), the patient 
undergoes digital rectal examination to estimate the gland volume and anatomy of the tissue, 
followed by a local determination of the stage of the tumor (Cheng et al., 2012). Additionally, 
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a prostate biopsy confirms the diagnosis (Ukimura et al., 2013). Based on the results, the 
pathological stage and Gleason score, which grades the level of cancer cell differentiation and 
aggressiveness of the tumors (Epstein et al., 2016) are determined, and finally treatment 
options are evaluated. 
Treatment strategies for prostate cancer depend on the stage and grade of the disease, 
in addition to the patient characteristics such as age, general condition, and additional 
treatments (Epstein et al., 1994; Heidenreich et al., 2014). Prostate tumors are often slow-
growing, providing many opportunities for therapeutic intervention. The treatment options 
can be classified into two categories depending on the local or advance stage of the disease 
(Kirby et al., 2006). The majority of localized or regional cancers in early stages can be cured 
by radical prostatectomy or radiation therapy. These treatments significantly increase the 
patient’s 5-year relative survival to nearly 100% (Jemal et al., 2010). If the disease has 
already spread outside the prostate, metastasizing, its progression can be delayed by surgery, 
androgen deprivation therapy, or a combination of both (Attard et al., 2016). Despite these 
treatments, a considerable proportion of patients will eventually develop castration-resistant 
prostate cancer, which at the moment is incurable (Scher and Sawyers, 2005), with a median 
overall survival of 18 months (James and Mason, 2015).  
The currently used diagnostic markers for prostate cancer have limitations such as lack 
of specificity, accuracy, and predictive value, not being able to identify and stratify patients 
and generating false-positive results (Attard et al., 2016). Although the PSA test is considered 
to be organ-specific and has a prognostic value, the test is not truly prostate cancer-specific, 
which limits its usefulness. PSA fails to distinguish between indolent and aggressive prostate 
cancer as well as growth from benign prostate hyperplasia (Catalona, 1994; Collins et al., 
1997; Thompson et al., 2005). Although the ratio of free vs total PSA and other parameters 
including PSA density, velocity, or doubling time of different PSA isoforms have been 
suggested to overcome these limitations, the use of these tests is not applicable in all cases 
(Artibani, 2012). Likewise, tests including the evaluation of PCA-3 in urine (Vlaeminck-
Guillem et al., 2010), early prostate cancer antigen in serum (Dhir et al., 2004; Paul et al., 
2005), and protein kinase C alpha in tissue (Perry A S et al., 2014), have not yet undergone 
systematic validation in large patients cohorts. Alternative strategies for biomarker discovery 
are clearly needed, and EVs could be considered as a new source for better predictive 
biomarkers. EVs have gained considerable attention as candidate biomarkers for diagnosis 
and prognosis of cancer, and multiple studies have documented their roles in different cancer 
types including prostate cancer.  
 
 
?????? ??????????????????????????????????
Prostate cancer is one of the most studied cancer models, and hence research of 
prostate cancer-derived EVs has exponentially increased over the years. As previously 
summarized in Tables I and II, several EV molecules have been proposed as candidate 
markers for early diagnosis, prognosis, screening, efficacy, and response to therapy. In 
addition, markers to discriminate the pathological stages of the disease, including metastatic, 
localized, and castration-resistant prostate cancer have been suggested. Currently, prostate 
cancer EV research is mainly based on studies performed with clinical samples e.g., plasma-
/serum-, urine-, semen- and prostatic secretions; tissue samples e.g., primary and metastatic 
tumors; cell lines e.g., DU-145, LNCaP, PC-3; and prostate cancer xenografts animal models. 
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Epithelial cells lining the prostate release vesicles termed prostasomes that belong to 
the EV family. Prostasomes are a very specific subset of neuroendocrine-like vesicles, of 
around 150 nm in average diameter, isolated from seminal and/or prostatic fluid (Duijvesz et 
al., 2011; Stridsberg et al., 1996). They are stored in the MVBs of acinar cells of the prostate 
gland and released after fusion with the plasma membrane (Ronquist et al., 2012). 
Prostasomes are positive for EV markers, including CD9 and CD63, but also other markers 
such as prostate-specific membrane antigen (PSMA), CD38, annexin A1, CD46, CD55, and 
CD59. The prostasome morphology is also thought to be different than that of other EVs 
(Poliakov et al., 2009), as well as their lipid composition (Arvidson et al., 1989; Duijvesz et 
al., 2011) and membrane structure (Stridsberg et al., 1996). In addition to the main role of 
prostasomes in human reproduction, they also appear to be involved in prostate cancer 
progression, for instance inducing invasion, migration, angiogenesis, and inhibition of the 
immune system (Aalberts et al., 2013). Overall, gaining knowledge about the EV content of 
prostate cancer tumors with different metastatic potential could be used for new diagnostic 
approaches. Proteomic and transcriptomic studies using prostate cancer-derived EVs are 
summarized here.  
Proteomic analysis has been mainly based on studies of EVs from various prostate 
cancer cell lines and clinical samples. EVs isolated from PNT2, Du145, RWPE-1, PC-3, VCaP, 
and LNCaP cell lines have been extensively studied, identifying proteins linked to tumor 
invasiveness, diagnosis, and prognosis. These proteins include: CD151, disintegrin and 
metalloproteinase domain 10 (ADAM10), ADAM15, calmodulin-ubiquitin domain-containing 
protein 1, annexin A2, calsyntenin 1, filamin C, PSMA, growth differentiation factor 15, fatty 
acid synthase (FASN), and exportin 1 (Duijvesz et al., 2013; Hosseini-Beheshti et al., 2012; 
Jansen et al., 2009; Sandvig and Llorente, 2012). Using a novel aptamer platform, Notch3, l1 
cell adhesion molecule, Ras-related C3 botulinum toxin substrate 1, ADAM9, milk fat 
globule-EGF factor 8 protein, and inter-α-trypsin inhibitor heavy chain family member 4, 
were identified as new cancer-associated proteins from prostate cancer-derived EVs (Webber 
et al., 2014). On a functional level, active packing of αvβ6 integrin in prostate cancer-derived 
EVs and its transfer to negative αvβ6 cells, was found to be able to promote cell migration 
(Fedele et al., 2015). In spite of the significance of these findings, only a few proteins have 
been positively validated in EVs isolated from patient samples. Among those proteins, several 
have been identified in EVs from the urine of prostate cancer patients. First, PSMA and PSA 
were detected in urine-derived EVs from prostate cancer patients (Mitchell et al., 2009). 
However, the presence of PSA in EVs could also be attributed to a possible contamination of 
soluble proteins in the EV preparation, as suggested by other groups (Jansen et al., 2009). 
Urine-derived EVs from prostate cancer patients have been found to contain increased 
amounts of certain proteins such as δ-catenin and FASN compared to controls without 
disease (Lu et al., 2009; Principe et al., 2013). Similarly, increased levels of α3-integrin and 
ß1-integrin were identified in the urine-derived EVs of metastatic prostate cancer patients 
compared to patients with a non-metastatic disease and/or benign prostate hyperplasia 
(Bijnsdorp et al., 2013). Detection of transmembrane protein 256 alone or in combination 
with late endosomal/lysosomal adaptor in urine EVs from prostate cancer patients has 
recently been proposed to increase the sensitivity and specificity of prostate cancer detection 
(Overbye et al., 2015). Moreover, detection of flotillin 2 and parkinsonism associated 
deglycase have been suggested to help distinguish between prostate cancer patients and 
healthy individuals (Wang et al., 2016). In line with those findings, a relevant discovery 
showed that EVs isolated from Du145 cells expressing PTEN protein could transfer their 
tumor suppressor cargo to PTEN negative prostate cells, thereby reducing proliferation and 
Literature review 
 
 20  
 
apoptosis of cancer cells (Gabriel et al., 2013). Apparently, the transport of PTEN was an 
exclusive property of DU145 EVs, which contained an active form of the enzyme that 
phosphorylates the protein, which remained functional and protected from enzymatic 
degradation. Most importantly, these findings were further validated in EVs from plasma of 
prostate cancer patients compared to healthy volunteers, with a further correlation between 
PTEN expression in EVs and the Gleason Score of the patients (Gabriel et al., 2013). In 
addition to PTEN, the inhibitor of apoptosis, survivin, and PSMA have also been found to be 
differentially present in the plasma of prostate cancer patients compared to patients with 
benign prostate hyperplasia (Khan et al., 2012; Park et al., 2016). Likewise, the cytochrome 
P450 17A1 protein was highly expressed in the serum from prostate cancer patients 
compared to the serum of healthy controls, highlighting the potential use of EV-borne 
prostate cancer-specific proteins in the early detection of prostate cancer (Locke et al., 2009). 
In addition to EV protein markers, comprehensive transcriptomic studies examining 
the role of EV-associated RNA species, including mRNAs, miRNAs, and lncRNAs have been 
performed and extensively reviewed (Hessvik et al., 2012; Soekmadji et al., 2013). In the 
context of urological cancers, EV-associated miRNAs have attracted the most attention. 
Many miRNAs isolated from plasma, serum, urine, prostatic secretions, and prostate cancer 
cell lines have been proposed as putative biomarkers for prostate cancer. However, the 
majority of the studies did not elucidate in which form the miRNAs were present, or if they 
were associated with EVs. Some examples include: miR-141, the first reported potential 
marker for prostate cancer diagnosis, progression, and metastatic staging (Brase et al., 2011; 
Mitchell et al., 2008); miR-1290 and miR-375 with survival prognosis in castration-resistant 
prostate cancer patients (Huang et al., 2015); miR-34a, for detecting the response to 
docetaxel treatment (Corcoran et al., 2014); miR-10a for the prediction of prostate cancer 
irrespective of androgen activity (Hessvik et al., 2012); and miR-141 and miR-375 for 
diagnosis (Bryant et al., 2012), although impure EVs were included in the study. On the other 
hand, the use of EV-associated mRNAs as possible biomarkers in prostate cancer has also 
been evaluated. Transmembrane serine protease fusion gene v-Ets avian erythroblastosis 
virus E26 oncogene homolog (TMPRSS2-ERG) mRNA transcripts were found in EVs isolated 
from prostate cancer cells (Jansen et al., 2009) and urine-derived EVs from prostate cancer 
patients. Urine-derived EVs from prostate cancer patients were also highly enriched in PCA-
3, type II, TMPSS2-ERG, and anterior gradient 2 mRNAs (Dijkstra et al., 2014; Neeb et al., 
2014; Nilsson et al., 2009). Moreover, mRNA transcripts of cadherin 3 (CDH3) were 
identified in urine-derived EVs from prostate cancer patients compared to patients with 
benign prostate hyperplasia. Genomic, transcriptional, and epigenetic alterations of the 
CDH3 expression showed a correlation between the decrease in abundance of CDH3 in EVs 
and the mRNA changes in the prostate tumor cells (Royo et al., 2016). Recently, a prostate 
cancer-screening test “ExoDx Prostate Intelliscore” from Exosome Diagnostics was proposed 
as a novel non-invasive test designed to predict the aggressiveness of prostate cancer. The 
test is based on the detection of ERG, PCA-3 and SAM pointed domain containing ETS 
transcription factor mRNAs in urine exosomes in combination with standard clinical 
parameters used to diagnose prostate cancer (McKiernan et al., 2016). Aside from the 
previously described molecules, DNA represents a more unexplored source of biomarkers. 
The first evidence of prostate vesicles carrying DNA was reported by Ronquist and 
collaborators in prostasomes (Ronquist et al., 2012; Ronquist et al., 2009), revealing the 
potential of EV-associated DNA in biomarker discovery.  
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???? ?????????????????????????????
?????? ???????????????????????????????????????????????????????????
Based on the EV molecular composition and participation in intercellular 
communication processes, EVs from specific cell types may serve as novel tools for several 
therapeutic approaches, including immune-modulatory and regenerative therapies, anti-
tumor therapy, pathogen vaccination, and drug delivery. Depending on their origin, EVs have 
both immune-activating and immune-suppressing properties. Immune activation can be 
relevant in immunotherapeutic applications, since EVs may promote the release of pro-
inflammatory cytokines and the activation of immune cells (Théry et al., 2009). On the other 
hand, some EV-associated molecules such as IL-10, IL-12, TGF-β, and Fas-ligand have 
immune-suppressive properties, for instance inducing T cell apoptosis and inhibiting 
inflammation, which may be relevant in systemic inflammation as well as in 
neurodegenerative and autoimmune diseases (Andaloussi et al., 2013). The innate ability of 
EVs to modulate immune responses by, for instance, the participation of EVs derived from 
dendritic cells in antitumor responses, makes them especially good candidates to be used in 
cancer vaccination.  
 
Immune-modulatory and regenerative therapies 
The use of mesenchymal stem cells (MSC) as a cell therapy has intensively been 
investigated in many clinical trials for their immunosuppressive and regenerative effects 
(www.ClinicalTrials.gov database). It is now becoming evident that the biological effects of 
MSCs are caused by their secretome, including the EVs (Fais et al., 2016).  
The use of MSC-derived EVs as a cell surrogate therapy has several advantages over 
therapies with stem cells, and MSC-derived EVs are under investigation for multiple 
inflammatory conditions as well as autoimmune and chronic diseases as recently reviewed 
(Lener et al., 2015). For instance, EVs from adipose-derived stem cells have shown 
therapeutic potential to treat Alzheimer's disease since they contain enzymatically active 
neprilysin, which lowered the levels of β-amyloid peptide secreted by neuroblastoma cells 
(Katsuda et al., 2013). Likewise, EVs derived from other cell types have also shown 
characteristics that could be exploited for therapeutic purposes. For instance, natural killer 
cell-derived EVs were shown to contain killer proteins that could induce tumor cell death 
(Lugini et al., 2012).  
 
Cancer vaccines 
Another area of EV research focuses on the use of EVs as cancer vaccines. EVs fulfill the 
entire antigen presenting requirements for a cell-free vaccine. Completed and still running 
clinical trials of EV-based therapies have been recently summarized (Ohno et al., 2016). The 
first study of EVs as cancer vaccines in 1998 showed the suppression of murine tumor growth 
in a T cell-dependent manner by dendritic cell-derived EVs pulsed with tumor peptides 
(Zitvogel et al., 1998). This discovery led to two phase I clinical trials where antigen-loaded 
EVs derived from immature dendritic cells were used to treat metastatic melanoma patients 
(Escudier et al., 2005) and advanced non-small cell lung cancer patients (Morse et al., 2005). 
However, although in both studies EVs showed a low cytotoxic effect, no specific response 
against the tumor was detected, and only a small number of patients benefited from the 
therapies. As a result, a phase II study based on EVs isolated from mature dendritic cells was 
used to treat advanced non-small cell lung cancer patients (Viaud et al., 2011). The study 
showed that EVs alone or EVs co-injected with immune-stimulatory adjuvants efficiently 
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promoted naïve T cell priming. Using a different approach, a phase I clinical trial based on 
the combination of ascites tumor-derived EVs with granulocyte-macrophage colony-
stimulating factor as an immune-stimulatory adjuvant, resulted in beneficial antitumor 
dendritic cell activity in patients with advanced colorectal cancer (Dai et al., 2008). Recently, 
results obtained in preclinical studies showed improved anti-tumor effect of dendritic cell-
derived EVs by using natural killer T cell activating agents (Gehrmann et al., 2013). Also, new 
vaccination strategies have been developed based on EVs from non-mammalian cells, 
including bacterial outer membrane vesicles and plant vesicles as therapeutic carriers against 
cancer and infectious diseases (Ohno et al., 2016). These approaches have entered phase I 
clinical trials and are currently under evaluation. For example, the use of outer membrane 
vesicles as a vaccine to treat meningitis recently concluded the phase II clinical trials 
(Findlow et al., 2010), with a highly promising protection of infants from meningitis. Taken 
together, these studies open new and exciting possibilities for EVs as immunotherapeutic 
agents. 
 
 
?????? ??????????????????????
Current challenges in drug delivery 
The most extensively used drug delivery platforms are lipid-based nanoparticles, 
including solid lipid nanoparticles and liposomes. Liposomes are considered to be the most 
successful drug-carrier systems to date (Felice et al., 2014). They are artificial uni-lamellar or 
multi-lamellar spherical vesicles of 20 nm to more than 1 μm, primarily comprising 
phospholipids, either from plant or animal sources (Felice et al., 2014; Maximilien et al., 
2015). Due to their resemblance to cellular membranes and their ability to incorporate drugs, 
liposomes have been widely studied in the delivery of pharmaceutical compounds for more 
than 50 years. They possess several benefits such as biodegradability, biocompatibility, and 
they are easily modifiable, facilitating specific cell targeting, which makes them valued as 
optimal delivery systems (Bozzuto and Molinari, 2015). Currently, several liposomal 
formulations have been used as medicines in the clinics, including the first FDA-approved 
Doxil®, a PEGylated doxorubicin liposome formulation for the treatment of solid tumors, 
and Marqibo®, the latest FDA approved liposome formulation which is a 
sphingosomal/cholesterol encapsulation of vincristine sulphate for the treatment of 
Philadelphia chromosome-negative acute lymphoblastic leukaemia (Allen and Cullis, 2013; 
Maximilien et al., 2015). Despite the extensive study of liposomes for more than five decades, 
there are still unresolved problems, and only a limited amount of liposomal drugs are 
approved for clinical use (Allen and Cullis, 2013). Important limitations are the toxicity at 
repeated administration, immunostimulation, complement activation, and the lack of batch-
to-batch reproducibility (Bozzuto and Molinari, 2015; Fais et al., 2016). Notably, lipid- and 
polymer-based nanoparticles have limited specificity and do not exhibit sufficient targeting at 
the cellular level to extrahepatic tissues, failing to combine intracellular drug delivery efficacy 
with biocompatibility (Stremersch et al., 2016a). Their limited ability to penetrate organs and 
tissues outside the reticuloendothelial system is also a major downside (Bozzuto and 
Molinari, 2015; Fais et al., 2016). Therefore, efforts are now focused on new therapeutic 
possibilities to overcome the current liposomal formulation drawbacks. 
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Advantages of EVs as drug carriers 
As outlined in section 2.1.4, EVs mediate signaling responses between cells and their 
surroundings by delivering a wide variety of active biomolecules. EVs possess several 
interesting features that make them ideal carriers of therapeutic drugs (Table III). Due to 
their natural origin, they surpass the stability, toxicity, and immunostimulation problems of 
current liposomal formulations. Other advantages also include their efficient internalization 
by recipient cells, and their natural ability and tropism to target specific cells or organs (Ha et 
al., 2016; Stremersch et al., 2016a). 
 
 
Table III. Advantages of EVs in drug delivery 
 
???????????????? ?????????
Protein/lipid architecture Protect encapsulated cargo 
 Contribute to the stabilization in blood 
 Modify the pharmacokinetics and biodistribution of the cargo 
 Stimulates uptake 
 Intrinsic cell tissue and targeting properties 
Nano size Minimizes the recognition by the reticuloendothelial system 
 Suitable administration via various routes 
Natural origin Reduce activation of adaptive immune system 
 Biocompatibility and biodegradability 
 
Adapted from (Fais et al., 2016; Ha et al., 2016; Stremersch et al., 2016a). 
 
 
The prospective use of EVs as customizable drug carriers and delivery vehicles has 
appealing potential, and several studies have unraveled their role in different aspects of their 
therapeutic use, as discussed below. 
 
Applications of EVs as drug delivery vehicles 
Due to their numerous advantages, EVs are now being explored as new therapeutic 
opportunities to carry and deliver several drug types, and these applications have been 
reviewed by Johnsen et al., 2014 and Stremersch et al., 2016a. EVs can carry a wide variety of 
molecules, including macromolecules such as DNA, RNA, and proteins, and small molecules 
e.g., doxorubicin, curcumin, or paclitaxel (Fais et al., 2016), improving the pharmacokinetic 
profile of the encapsulated therapeutic compounds by protecting the drug from degradation 
and/or early release. Currently, different strategies exist to load the therapeutic cargo within 
the EVs. These approaches can be based on pre-EV formation, where the therapeutic cargo is 
first loaded into EV producing cells packing the cargo during their biogenesis, or post-EV 
formation, where isolated EVs are loaded with the cargo via electroporation, passive 
incubation, or destabilizing of the EV membrane (Stremersch et al., 2016a; Vader et al., 
2014). The therapeutic cargo delivered by EVs can be classified into macromolecular drugs, 
including nucleic acids and proteins, and small molecular drugs. 
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-? Nucleic acids and proteins 
Plasmid vectors expressing the therapeutic cargo in cells such as mRNA (Zomer et al., 
2015), miRNA (Kosaka et al., 2010), siRNA (Liu et al., 2015), and the transfection of the 
producer cell with the cargo (Zhang et al., 2010), are some of the commonly used approaches 
to load nucleic acids in EVs before their formation. Proteins can be specifically sorted into 
EVs by creating fusion constructs which contain the protein of interest bound to EV-
associated proteins such as platelet-derived growth factor receptor (Ohno et al., 2012), 
lactadherin (Estelles et al., 2007; Rountree et al., 2011), or lysosomal associated membrane 
protein 2b (LAMP-2b) (Alvarez-Erviti et al., 2011; Tian et al., 2014a). Post-EV formation 
loading approaches have also been used for nucleic acids. A pioneering study reported the 
electroporation of siRNA into dendritic cell-derived EVs, and its functional delivery through 
the blood-brain barrier in a murine model of Alzheimer's disease (Alvarez-Erviti et al., 2011). 
Since then, several reports have shown successful loading of nucleic acids into EVs and their 
efficacy in targeted cells (Chen et al., 2015; Cooper et al., 2014; Lamichhane et al., 2015; 
Shtam et al., 2013; Wahlgren et al., 2012). Novel drug delivery strategies such as decorating 
EVs with therapeutic nucleic acids, including cholesterol-conjugated siRNA (Stremersch et 
al., 2016c) and hydrophobically modified siRNAs (Didiot et al., 2016) are now also being 
explored. 
 
-? Small molecular drugs 
The use of EVs as carriers of small molecular drugs could be of a great advantage, since 
EV-loading can significantly reduce the dose requirement and increase the specificity of 
targeting, thereby decreasing the side effects of toxic cancer treatments. The loading of drugs 
into EVs has been accomplished using both pre- and post-EV formation methods. Using the 
pre-EV formation approach, MSCs incubated with free paclitaxel produced paclitaxel-loaded 
EVs with anti-proliferative effects in vitro (Pascucci et al., 2014). Similarly, EVs secreted by 
cisplatin-treated tumor cells carried cisplatin within their cargo (Federici et al., 2014). The 
simple incubation of EVs at ambient or high temperatures with hydrophobic membrane-
permeable drugs, such as curcumin and doxorubicin, exhibited a high drug loading efficiency 
and an increase in the cytotoxic effect of the loaded EVs compared with the free drugs (Sun et 
al., 2010; Yang et al., 2015). Interestingly, plant-derived EVs loaded with curcumin are now 
under clinical examination to treat colon cancer (Ohno et al., 2016), Membrane-destabilizing 
methods have also been used to lead drugs into EVs. For instance, EVs bearing an iRGD 
targeting peptide were loaded with doxorubicin by electroporation and then administered to 
mice harboring αv integrin-positive tumors, which led to a significantly reduced tumor size 
(Tian et al., 2014a). Different loading strategies including permeabilization with saponin, 
sonication, freeze-thaw cycles, incubation, or extrusion were used to compare the loading of 
small molecules such as porphyrins (Fuhrmann et al., 2015) and macromolecules like 
catalases (Haney et al., 2015) and their phototoxic and neuroprotective effects in recipient 
cells, respectively.  
 
 
???? ?????????????????????????????????????????????????????????????????
Based on the above evidences, EVs have a promising future as both prospetive 
biomarkers for different diseases including cancer, as well as therapeutic tools for 
personalized medicine (Figure 5). The presence of EVs in the circulation of both healthy and 
sick individuals reveals the role of EVs as messengers to transport and deliver information to 
different cells in the body, contributing not only to the regulation of normal physiological 
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body functions, but also to the spreading of the diseases. The review of the literature 
presented above showed striking evidences supporting the use of EV content in the context of 
biomarker discovery, early diagnosis, disease monitoring, and treatment. The personalized 
information of EVs isolated from individual patients, including EV proteome, metabolome, 
transcriptome, and genome profile, and the ability of EVs to influence cell transformation, 
will help to tailor specific integrated diagnostics platforms and treatment strategies. Despite 
these evidences, a more comprehensive understanding of the role of individual EV 
subpopulations in the heterogeneous mix of EVs constituting the tumor secretome will 
undoubtedly provide new perspectives on using EVs as diagnostic tools. 
Taking advantage of the self-derived nature of patient EVs, they could also be used to 
treat previously diagnosed diseases by tailoring an individual and more specific treatment 
plan with reduced side effects. The future of the clinical use of EVs depends upon further 
investigation and interdisciplinary collaboration among researchers, since EV-mediated 
diagnostics and therapeutics are still in their early stages, and further investigation is needed 
before it can be translated into the clinics. 
 
 
 
Figure 5. Schematic representation of personalized approaches for prostate cancer diagnostics 
and therapeutics using EVs. Cancer-derived EVs present in blood and other fluids represent a 
potential source of cancer markers, containing specific information of the tumors. Screening platforms 
based on the analysis of the composition of EVs isolated from biofluids of individual cancer patients, 
the so-called “liquid biopsy”, will open up new possibilities in the fields of cancer diagnosis and 
treatment. Alternatively, EVs could potentially be harvested from exogenous sources (allogenic) or 
from the own patient (autologous) and exploited as therapeutics or for the delivery of drugs. The figure 
was produced party using Servier Medical Art. 
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?? ?? ???????????????
The overall aim of this thesis was to evaluate the applicability and functional relevance 
of EVs as a source of biomarkers and as therapeutic drug carriers using prostate cancer as a 
disease model. 
 
The detailed aims of this thesis were: 
 
?? To investigate the nucleic acid cargo of EV subpopulations, particularly gDNA and 
mRNA, as a possible source of prostate cancer biomarkers (I, II). 
 
?? To evaluate the role of prostate cancer cell-derived EVs in cell-to-cell communication 
(III). 
 
?? To assess the usability of EV subpopulations as drug delivery carriers (IV). 
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?? ??????????????????????
The materials and methods used are described in this chapter. The more detailed 
description of the experimental procedures can be found in the original publications I–IV. 
 
 
???? ???????????????????????????????????????????????????
Table IV. Human cell lines used in the studies. ?? ??
?????????? ?????????? ???????????????? ??????? ???????? ????? ????????????
LNCaP     
(CRL-1740) 
prostate 
cancer 
epithelial  
derived from 
metastatic site: 
supraclavicular 
lymph node 
ATCC2 
RPMI 1640 medium 
supplemented with 10% 
EV-depleted fetal 
bovine serum 
I, II, III, IV 
PC-3                      
(CRL-1435) 
prostate 
cancer 
epithelial  
derived from 
metastatic site: 
bone 
ATCC2 
DMEM/F12 medium 
supplemented with 10% 
EV-depleted fetal 
bovine serum 
I, II, III, IV 
PNT2 
normal 
prostate 
epithelial  
immortalized  
with SV40 ECACC
3 
Keratinocyte-SFM with 
bovine pituitary extract 
and human 
recombinant epidermal 
growth factor 
II, III 
RC92a/hTERT1 
prostate 
cancer 
epithelial 
primary cells 
immortalized  
with hTERT 
Dr. Rhim4 
Keratinocyte-SFM with 
bovine pituitary extract 
and human 
recombinant epidermal 
growth factor 
I, III 
 
1RC-92a/hTERT cells were obtained from radical prostatectomy specimen according to Water Reed Medical 
Center and Uniformed Service University of the Health Sciences Internal Review Board Protocol. RC-92a tumor 
cells were obtained from a 57-year-old Caucasian patient who had clinical stage B0 and Gleason 3+3. 
2American Type Culture Collection (ATCC), Masanasas, VA, USA 
3European Collection of Authenticated Cell Cultures (ECACC), Salisbury, UK 
4Provided by Dr. Rhim JS, Center for Prostate Disease Research, University of the Health Sciences, Bethesda, MD, 
USA 
 
 
For publication III, cell index-doubling times of PC-3 and PNT2 cells were analyzed 
using RTCA iCELLigence machine (ACEA Biosciences). Prostate cells were seeded on E L8 
PET-plates in 2-fold dilution series (40,000 to 5,000 cells/well) as recommended by the 
manufacturer. After cell attachment, the plates were analyzed using the proliferation 
program of the iCELLigence instrument. RPMI 1640 and DMEM/F12 cell culture media were 
supplemented with 10% EV-depleted fetal bovine serum (FBS). The FBS was EV-depleted by 
centrifugation at 110,000 x gavg for 16–18 h using 50.2 Ti or 45 Ti rotors, followed by 
filtration through a 0.22 μm filter. 
 
 
???? ????????????????????
EDTA-blood samples were obtained from prostate cancer patients (for patient 
characteristics see publication I), and healthy male donors after receiving written consent 
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(ethical permission number R03203 from the Tampere University Hospital). Plasma samples 
were obtained after centrifugation of the whole blood two times at 2,500 x g for 15 min. 
 
 
???? ?????????????????????????
The primary antibodies used in publication II, III, and IV are summarized in Table V. 
For a more complete description of the concentrations and conditions used refer to the 
publications. 
 
?Table V. List of antibodies used in the studies. ?
?????????
?????? ?????????????????????? ???????????? ??????? ????????????
GM130 Golgi apparatus stack 
membrane 
Immuno-
fluorescence 
Cell Signaling 
MA, USA 
III 
EEA1 Cytoplasm and early endosome 
membrane 
Lamp1 Cell, endosome and lysosome 
membranes 
IOWA University 
USA 
CD44 
Membrane 
Dr. Jalkanen 
Turku, Finland 
CD9 
Western 
blotting 
Santa Cruz 
Biotechnology 
 CA, USA 
III, IV 
CD81 II, IV 
Calnexin Endoplasmic reticulum 
membrane II 
Flotillin-I Cell membrane. Membrane-
associated protein of caveolae. 
Endosome 
II 
GAPDH Cytoplasm, cytosol, perinuclear 
region. Membrane III, IV 
CD63 Lysosomal associated 
membrane protein  III, IV 
HSP70 Cytoplasm. Localized in 
cytoplasmic mRNP granules 
BD Biosciences 
USA 
III 
Tubulin Major constituent of 
microtubules IV 
TSG101 
Mainly cytoplasm, membrane, 
and late endosome membrane  
mRPN: messenger ribonucleoprotein 
 
 
???? ??????????????????????????????
?????? ?????????????????????????????
Cell-conditioned media from the above mentioned cell lines and plasma samples were 
subjected to differential ultracentrifugation to isolate EV-enriched subpopulations (Figure 
6). Cell conditioned media was collected when the cells reached 80% confluence, and 
centrifuged at 1,000 x g for 10 min to remove cell debris. The remaining supernatant was 
carefully collected and centrifuged at 2,500 x g for 25 min (1,200 x g in publication I) to 
pellet ABs. The supernatant was then centrifuged at 20,000 x gavg for 60 min (SLA 1500 
rotor, Sorvall, in publications I, III, and IV) or 25 min (45 Ti rotor, Beckmann Coulter, in 
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publication II) to pellet MVs. The remaining supernatant was filtered through 0.22 μm filter 
(only publication I) and centrifuged at 110,000 x gavg for 1 h (publication I and IV) or 2 h 
(publications II and III) using 50.2 Ti or 45 Ti rotors to pellet EXOs. The centrifugation time 
was increased from 1 h to 2 h in order to increase the yield of EXOs recovered during 
isolation. The completed cell media that has not been in contact with cells was also subjected 
to EV isolation and used as a control. Particle counts close to background levels of buffers 
were identified, and the remaining particle counts were at least 100-fold lower compared to 
EV samples. 
In these four studies I will refer to EVs as a general term that encompasses all EV 
subtypes. The term EXOs will be used when referring to enrich vesicles of endosomal origin 
pelleted at 110,000 x g. The term MVs will refer to enriched vesicles pelleted at 20,000 x g, 
that are formed by outward budding of the cellular plasma membrane. The term ABs will 
refer to vesicles generated from apoptotic cells, pelleted at lower speeds 1,000–2,500 x g. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Experimental flow-chart of the isolation of prostate cell-derived and plasma-derived 
EV subpopulations. After cell debris removal or plasma separation from the whole blood, the samples 
were subjected to a differential centrifugation protocol, to obtain ABs: apoptotic bodies, MVs: 
microvesicles, and EXOs: exosomes. EV pellets were immediately stored at -80 °C or alternatively 
were freshly used, as indicated in the studies. The publication numbers are displayed in parenthesis. 
CCM: cell-conditioned media. 
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???? ?????????????????????????????????????
?????? ??????????????????????????????????????????????????
For transmission electron microscopy (TEM) analysis, EV samples were incubated onto 
formvar glow-discharged copper grids for 2 min at 4 °C. Grids were washed, blotted dry with 
filter paper, and negatively stained with 2% aqueous uranyl acetate (Sigma-Aldrich). 
Following washes, samples were dried in darkness for 20 min and analyzed using FEI Tecnai 
Spirit G2 (Soft Image System Morada camera) and Tecnai 12 (Gatan Orius SC 1000B bottom 
mounted CCD-camera) operated at 80 kV. 
For Cryo-TEM analysis (publication IV), glow-discharged carbon grids were first 
purified with the Solarus plasma cleaning system (Gatan) and blotted with 3 μL of EV 
samples. Samples were vitrified in liquid nitrogen using Vitrobot (FEI) and imaged using a 
JEOL JEM-3200FSC instrument operated at 200 kV. 
 
?????? ???????????????????????????????????????????????????????????????
The size distribution and particle concentration of the EV preparations were analyzed 
using the Nanoparticle Tracking Analyzer (NTA) instrument (Malvern Instruments Ltd, 
Malvern, UK) with LM10 view unit and red laser (638 nm, 40mW) (publication I) or with a 
LM14 view unit, blue laser (405 nm, 70mW) (publications III and IV) and a CMOS camera 
(Hamamatsu Photonics, Hamamatsu, Japan).?Equipment settings for data acquisition, which 
were optimized based on the EV source, were kept constant between measurements: camera 
level 13–14, auto settings off, polydispersity and reproducibility high with 40–100 particles 
per image, acquisition time three 90 s videos, screen gain 10 and threshold 10. Data analysis 
was performed with NTA 2.3 software (NanoSight, Amesbury, UK). 
For zeta potential measurements (publication IV), EV samples were diluted with 
DPBS and the pH was adjusted to 7.4. Samples were transferred to the capillary cell DTS1070 
(Malvern, Worcestershire, UK) and measured at 25 °C using a Zetasizer Nano ZS (Malvern). 
 
?????? ???????????????????? ?????????????????????????????????
EVs and cellular protein samples were lysed in RIPA lysis buffer (Thermo Fisher 
Scientific) supplemented with a protease inhibitor mixture (Sigma-Aldrich), and analyzed in 
triplicates using the BCA or MicroBCA protein assay kit (Pierce, Thermo Fisher Scientific) 
and Varioskan Flash multireader (v.2.4.3) with a 562 nm absorbance filter (Thermo Fisher 
Scientific). Western blotting samples were prepared with 2x Laemmli buffer (Bio-Rad) and 
heated at 95 °C for 5 min. 50–25 μg of protein from EVs and cells were loaded onto 12 % 
Mini-PROTEAN TGX™ gels (Bio-Rad) and transferred to Protran nitrocellulose membrane 
(Whatman International Ltd). Membranes were blocked in 5% (w/v) skim milk powder in 
Tris-buffered saline-0.1% Tween 20 (TBST) for 1 h to overnight. Blocked membranes were 
incubated with the primary antibodies diluted in 0.25–2.5% milk-TBS presented in Table V. 
The membranes were washed with TBST, and incubated for 45 min to 1 h at room 
temperature (RT) with the goat anti-mouse IgG-HRP (Santa Cruz Biotechnology) or the ECL 
donkey anti-rabbit IgG-HRP secondary antibodies diluted in 0.25–2.5% milk-TBST. 
Membranes were washed and incubated with Luminata Crescendo Western HRP Substrate 
(Millipore) or ECL Prime Western Blotting Detection (GE Healthcare Limited). Membranes 
were visualized on VersaDoc 4000 MP (Bio-Rad) or Amersham Hyperfilm ECL (GE 
Healthcare Limited). 
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?????? ??????????????????????????????????????????????????
EVs were labeled using 1–2 μg/mL of the following lipophilic aminostyryl dyes: 
DiIC18(5)-DS or SP-DiOC18(3) (Molecular Probes, Thermo Fisher Scientific). In publication 
IV, paclitaxel-loaded EV samples were double-labeled with DiD (Biotium) and OregonGreen-
paclitaxel (Invitrogen, Thermo Fisher Scientific) to study the cellular distribution of the drug 
-loaded EVs. The EVs were incubated with the dyes for 20–60 min at RT and the free dye was 
removed by size exclusion chromatography or ultracentrifugation at 110,000 x g. In 
publication III, samples were measured with Apogee A50micro for 120 sec with optimized 
settings. To demonstrate the specificity of the labeling protocol, labeled EVs were treated 
with 0.15% SDS and analyzed using FlowJo 10.0 software (Treestar, USA).   
 
?????? ?????????????????
DNA isolation, profiling and pre-amplification 
To remove possible external EV-associated nucleic acids, EV samples were treated with 
100 mg/mL of RNase A (Thermo Fisher Scientific) for 2 min at RT and 27 Kunitz U/mL of 
DNase I (Qiagen, Hilden, Germany) for 30 min at 37 °C followed by enzyme inactivation. 
Total DNA was extracted from EV and cell samples using the DNeasy Blood and Tissue kit 
(Qiagen) according to manufacturer´s instructions. The quality, profile, size, and 
concentration of the DNA samples was analyzed by capillary electrophoresis using a 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) with a High Sensitivity DNA kit 
and confirmed by SPECTROstar Nano (BMG Labtech). The total DNA was pre-amplified 
using the GenomePlex Complete WGA2 kit (Sigma-Aldrich, St Louis, MO, USA) following 
manufacturer’s recommendations. 
?
PCR and sequencing 
Conventional and quantitative PCR, together with Sanger sequencing were used to 
confirm and validate the presence of MLH1, PTEN, and TP53 genomic DNA sequences in EV 
subpopulations and cells. Specific primers (Sigma-Aldrich) were design using Primer 3 and 
nucleotide Blast (BLASTN, NCBI) tools, and the PCR conditions were optimized for each 
sample (I, Table II). Briefly, for conventional PCR, 10 ng of DNA was used per reaction and 
samples were run in a T100 Thermal cycler (Bio-Rad Laboratories, Hercules, CA, USA). For 
quantitative PCR assays, 50 ng of DNA mixed with the Fast SYBR Green Master Mix (Applied 
Biosystems) was run using a Lightcycler 480 (Roche Diagnostics). The melting curves and 
cycle threshold (Ct) values were analyzed with Lightcycler 480, v.1.5 software, and manually 
reviewed. Samples, external standards, and non-template controls were run in triplicate and 
the resulting PCR products were validated by electrophoresis in 1% agarose gels. The PCR 
products were extracted and purified using Gel extraction kit and QIAqick PCR purification 
kit (Qiagen) and sequenced using a BigDye Terminator v.3.1. Cycle Sequencing kit and ABI 
3730 DNA analyzer automated sequencer (Applied Biosystems). Sequencing results were 
analyzed using Geneious v 4.8.5 software. 
 
?????? ???????????????????
RNA isolation, profiling and pre-amplification 
Total RNA was extracted from EVs and cell samples using a miRNAeasy micro kit 
(Qiagen) as recommended by the manufacturer. The concentration, quality, and size of the 
RNA was measured by capillary electrophoresis after sample denaturation at 72 °C for 2 min, 
using RNA 6000 Nano and Pico total RNA kits and 2100 Bioanalyzer instrument (Agilent 
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Technologies). 500 ng of RNA were subjected to DNA removal, cDNA synthesis, and instant 
pre-amplification using the RT2 PCR System PreAMP and Human Prostate Cancer Pathway 
mix (Qiagen).  
 
Reverse transcription quantitative PCR (RT-qPCR) 
For RT-qPCR analysis, PAHS-135Z Human Prostate Cancer Pathway RT2 Profiler PCR 
Arrays (SaBiosciences, Qiagen) were used as described by manufacturer. 100 ng/μL of EV-
RNA samples mixed with the RT2 SYBR Green Master Mix were run in biological triplicates 
in a CFX96 thermocycler (Bio-rad). The 3.5 PCR Array Data Analysis software 
(SaBiosciences) was utilized to calculate the mRNA levels of each gene and compared to all 
the genes across the array (global normalization). A stringent fold-change threshold of 10 was 
used for the mRNA analysis. 
 
 
???? ??????????????????????????????????
EVs were loaded with 5 μM paclitaxel-DPBS solution by passive incubation at 22 °C for 
1 h. The unbound drug was removed by pelleting the EVs at 170,000 x g for 2 h, washing with 
DPBS, and pelleting them again at 170,000 x g for 2 h. Prior to the measurement, the 
acetonitrile extraction method was confirmed by spiking non-loaded EVs and 1.8 μM 
paclitaxel. To measure the loading efficiency of the EV-associated paclitaxel, samples were 
dissolved in acetonitrile, centrifuged at 10,000 x g to remove precipitates, and the 
supernatant was measured in the Acquity Ultra Performance Liquid Chromatography (UPLC) 
system (Waters). The in vitro drug release of the paclitaxel from EVs was analyzed in DPBS, 
pH 7.4, at 37 °C for 24 h and 48 h. Half of the volume of the release medium was withdrawn 
at each time point by ultracentrifugation of the EV samples at 170,000 x g for 2 h and 
collection of the supernatant, and the withdrawn medium was then replaced. The drug 
concentration of the supernatant was analyzed by UPLC. 
 
 
???? ?????????????????????????????????????
?????? ??????????????????????????????????????????????????
Automated cellular imaging system (III) 
Prostate cells were seeded in 96 well plates at a density of 3,000–4,000 cells/well. 
Cytoplasmic membranes were labeled with CellBrite Green Cytoplasmic Dye (Biotium), 
according to manufacturer´s instructions followed by incubation with 109 particles/mL of 
DiIC18(5)-DS labeled -EVs for different times. Prior to the analysis, cell samples were washed 
with DPBS, fixed with 4% paraformaldehyde at RT for 10 min, and analyzed by IN Cell 
Analyzer 1000 high-content system (GE Healthcare, Life Sciences) configured with a CCD 
camera and a 20×/0.45 NA objective. The percentage of cells with EVs was quantified using 
segmentation algorithms and normalized to the total number of cells per image. 
 
Flow cytometry (III, IV) 
Prostate cells were seeded in 6 well plates at 300,000–500,000 cells/well and 
incubated with DiIC18(5)-DS-labeled EVs. After incubation for different times, cells were 
washed twice with DPBS, harvested, fixed using high-grade cold 99% ethanol, and stored at -
20 °C overnight. After ethanol removal and re-hydration, samples were run in a Gallios flow 
cytometer (Beckman Coulter), collecting 20,000–100,000 events/sample and analyzed with 
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FlowJo. Unstained cells with and without EVs were used as negative controls to gate the 
positive populations based on forward- and size- scatter profiles. 
 
Confocal laser scanning microscopy (III, IV) 
Prostate cells were seeded in chamber slides and incubated with EVs for 16 h and 24 h. 
For the co-localization experiments in publication III, cells were fixed with 4% 
paraformaldehyde in 0.1 M DPBS for 20 min at RT, permeabilized using 0.1% Triton X-100 
in 1% BSA-DPBS for 10 min and blocked with 1% BSA-DPBS for 20 min. The cells were 
incubated overnight in blocking solution at 4 °C with the antibodies described in Table V. 
After washing, cells were incubated with the secondary antibody Texas red anti-mouse 
(1:100) or Texas red anti-rabbit (1:500) (Vector laboratories, CA, USA) for 1 h at RT. Nuclei 
were stained with DAPI (1 μg/mL, Sigma), and the samples were imaged with Zeiss Axio 
Observer inverted microscope (63×NA 1.4 oil immersion objective) equipped with Zeiss LSM 
800 confocal module (Carl Zeiss Microimaging GmbH, Jena, Germany). Image acquisition 
was done with ZEN2 software (Carl Zeiss Microimaging GmbH). Co-localization analyses 
were conducted using Imaris 7.7.2 software, by selecting DiIC18-EVs channel as region of 
interest (ROI). Thresholds were auto adjusted by the software within the ROI. The 
percentage of ROI material of DiI- co-localizing with CD44, EEA1, Lamp-1, GM130 markers 
was separately analyzed from at least eight images containing multiple cells. 
For the co-localization studies (publication IV), prostate cancer cells were incubated 
with free Oregon Green paclitaxel, DiO-labeled EVs or double-labeled paclitaxel-loaded EVs 
(as described in section 4.4.5) for 24 h or 48 h. Live cells were labeled with 70 nM of 
LysoTracker Red (Invitrogen, Thermo Fisher Scientific) for 2 h, followed by washes for dye 
removal. Image and video acquisitions were conducted using a High Content Screening 
Automation Leica TCS SP5II (Leica Microsystems) or a 3I Marianas (3I Intelligent Imaging 
Innovations) with a 63×NA 1.46 oil immersion objective. Confocal images were processed 
using Fiji Image J 1.49 software. 
 
?????? ?????????????????????????
The cytotoxic effect of the different concentrations of free paclitaxel and paclitaxel-
loaded EVs in prostate cancer cells (publication IV) was assessed using the AlamarBlue assay 
(Life Technologies, Thermo Fisher Scientific), measuring the fluorescent intensity with 
excitation at 560 nm and emission at 590 nm using Varioskan Flash Multimode Reader 
(Thermo Fisher Scientific). AlamarBlue uses the reducing power of living cells to 
quantitatively measure cell proliferation. The active ingredient resazurin is reduced to 
resofurin, which is red in color and highly fluorescent. 
For viability analysis by flow cytometry (publication III), cell samples were harvested 
in 2% FBS-DPBS solution, labeled with 7-Aminoactinomycin D (BD Pharmingen), which is a 
fluorescent intercalator that undergoes spectral shift upon association with DNA, and 
immediately analyzed. 
 
?????? ?????????????????
Prostate cancer cells were incubated with 109 particles/mL of SP-DiOC18(3)-labeled 
EVs.  Cells were washed, harvested, fixed using high-grade cold 99% ethanol, and stored at -
20 °C overnight. After ethanol removal and rehydration, samples were incubated with 3 μM 
propidium iodine (Molecular Probes, Thermo Fisher Scientific) in 4% FBS-DPBS for 15 min 
Materials and Methods 
 
 34  
 
at RT. Samples were run in a Gallios flow cytometer (Beckman Coulter) and analyzed using 
FlowJo. 
 
?????? ????????????????????
For analysis of proliferation of prostate cancer cells treated and non-treated with EVs 
(109 particles/mL), cells were seeded in 6 well plates at 300,000–500,000 cells/well and 
incubated with 5 μM CellTrace CFSE dye for 20 min at 37 °C. The residual dye was removed 
from the cultures by washing three times with DPBS, cell samples were harvested in 2% FBS-
DPBS solution and immediately run with a FACS Verse flow cytometer (BD Biosciences) and 
analyzed with FlowJo.  
 
?????? ????????????????
Prostate cancer cell migration was determined using a Radius fibronectin coated kit 24 
well assay (Cell Biolabs). Cells were seeded at 200,000 cells/mL and incubated overnight. 
After gel removal, 109 particles/mL of EVs were added, and the gap closure was monitored 
using a phase-contrast inverted EVOS XL microscope (Thermo Fisher Scientific) at 10× 
magnification. Cell migration images were analyzed using ImageJ 1.49v software.  
 
 
???? ??????????????????????????????????????
For publication I, statistical analysis was performed using R-project 3.0.2 software. 
Student’s t-test with a Shapiro-Wilk test or non-parametric Wilcoxon signed ranked test were 
used. For publication II and III, statistical analyses were performed using GraphPad Prism 
7.0 (GraphPad Software, San Diego, CA, USA). Unpaired student’s t-test, one-way or two-way 
ANOVA with Tukey's multiple comparisons test or Dunnett's multiple comparisons test were 
used. For publication IV, statistical analysis was carried out using SPSS 22.0 and SigmaPlot 
11.0. Paired and unpaired student’s t-test, one-way ANOVA with Tamhane’s T2 post hoc t 
test, and Mann-Whitney Rank Sum test were used. The results were considered statistically 
significant as follow: *P<0.05; **P<0.01; ***P<0.001, ****P<0.0001. All results are 
presented as mean ± standard error of the mean (SEM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
 35  
 
?? ????????
This chapter summarizes the main results of this thesis and the new results obtained 
after combining the studies. More details can be found in the original publications (I-IV). 
 
???? ??????????????????????????????????????????????????????????????????????????
?????? ????????????????????????????????
EV subpopulations from various prostate cell lines and human plasma samples were 
isolated by differential centrifugation. The protocol used in these studies (Figure 6) allowed 
the separation of three major enriched but heterogeneous EV subsets, namely ABs, MVs, and 
EXOs (I-IV, Fig. 1). ABs pelleted at the lower centrifugation speeds (1,200–2,500 x g), were 
usually the less abundant EV subsets as shown by TEM analysis. MVs, isolated at 20,000 x g, 
were heterogeneous lipid membrane particles with very diverse sizes and morphologies when 
analyzed by TEM. MVs had an average size of ~ 200–250 nm as shown by NTA analysis, with 
vesicles ranging from ~ 100–800 nm in diameter dependent on their source of origin. EXOs, 
obtained after ultracentrifugation at 110,000 x g, had a “cup-shaped” morphology when 
analyzed by TEM, which is now known to be an artificial artifact of the technique, and 
variable sizes ranging from ~ 50–200 nm when analyzed by NTA. When techniques that 
preserve the EV structure, such as Cryo-TEM, were used to characterize the EVs, a large 
diversity of sizes and morphologies were observed in the MV and EXO enriched 
subpopulations (IV, Fig. 2). Cryo-TEM analysis revealed highly electron dense vesicles with 
lipid bilayers and remarkable multi-structural vesicles, such as double vesicles, triple to 
sextuple vesicles, and vesicle-containing sacks. The amount of EVs released from LNCaP, PC-
3, RC92a/hTERT, and PNT2 cell lines was similar, around 5–50 x 109 particles/mL per 
million cells when NTA 2.3 software and LM14 view unit with blue laser were used to 
measure the samples. The variation of the EV amount was dependent on the cell source of the 
EVs, the incubation time of the culture media with the cells, and the EV subpopulation 
analyzed. In contrast, the total protein contents of the different cell line?derived EVs were 
different, with a possible influence of the protein carryover from the cell media. For instance, 
LNCaP, PC-3, and RC92a/hTERT MVs and EXOs had differences in their total protein 
content, depending on the cellular origin of the EVs and the vesicle subpopulation analyzed 
(I, Fig. 3), with MVs typically having a higher particle to protein ratio than EXOs. LNCaP and 
RC92a/hTERT EV particle numbers measured by NTA correlated well with the total protein 
content of the vesicles, whereas no correlation was apparent for PC-3 EVs. When prostate 
cancer patient samples were analyzed, the total concentration of EVs isolated from plasma 
samples of cancer patients was higher than that from healthy donors (I, Fig. 2). Analysis of 
the typical “EV-markers” from the prostate cancer cell-derived MVs and EXOs by western 
blotting showed the presence of protein markers such as CD9, CD63, CD81, and TSG101, 
common to both MVs and EXOs, but with enriched expression levels in comparison to the 
respective cell lysates when equal protein amount was analyzed (II-IV, Fig. 1). This data 
revealed qualitative differences of the markers, but it did not provide quantitative 
comparisons of EV numbers or their cargo between the cell lines due to the different media 
composition. 
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5.1.2? Differential nucleic acid cargo of EVs 
Next, the nucleic acid contents of these same prostate cell-derived EV subpopulations 
were investigated (I, II). ABs, MVs, and EXOs isolated from LNCaP, PC-3, PNT2, and 
RC92a/hTERT cells, had very similar total DNA and RNA nucleic acid profiles between 
different cell types, but these profiles were very different among the different subpopulations 
(Figure 7). Additionally, MVs and EXOs derived from the benign prostate epithelial PNT2 
cells displayed different RNA profiles from the EVs derived from prostate cancer cells of 
primary or metastatic origin (II, Fig. 1). Prostate cancer and non-cancer cell-derived EVs 
carried DNA and RNA fragments of variable sizes. DNA molecules were largely protected 
from enzymatic degradation, suggesting that the nucleic acid cargo analyzed resided mostly 
within the internal vesicle cargo. However, the RNA content of the EV subsets was comprised 
of both adsorbed RNA molecules to the EV surface and RNAs packed with the EV internal 
cargo. 
 
 
 
Figure 7. Characterization of the nucleic acid content of prostate cancer cell-derived EV 
subpopulations. Representative electropherograms for apoptotic bodies (ABs), microvesicles (MVs), 
and exosomes (EXOs) displaying the total double stranded (ds)DNA and RNA profiles analyzed by 
capillary electrophoresis using 2100 Bioanalyzer. The y-axes show fluorescence units (FU) and the x-
axes represents base pairs (bp) for DNA and nucleotide length (nt) for RNA. The DNA peaks at 35 and 
10,000 bp represent the lower and the upper internal DNA markers. The RNA peaks at 25 nt represent 
the internal standards used, and peaks around 2,000 nt and 4,000 nt represent ribosomal RNA 18 and 
28 subunits, respectively. 
 
 
Prostate cancer-derived ABs contained large and abundant fragments of double-
stranded DNA up to 10,000 bp, and were enriched in ribosomal RNA (rRNA) with a 
relatively low amount of small RNA molecules. MVs shared similar DNA and RNA profiles 
with the ABs. MVs contained smaller amounts of double-stranded DNA in comparison to 
EXOs, with DNA fragments ranging from 1,000–10,000 bp. The RNA profile of MVs 
fractions showed enrichment in rRNA, which was visible as 18S and 28S peaks, whereas 
small RNAs were less abundant compared to EXOs. In contrast, EXOs were enriched in both 
DNA and small RNA molecules. The DNA amount present in prostate cancer EXOs varied 
among samples. EXOs from prostate cell lines showed a distinctive DNA profile with a range 
of fragment sizes between 50–10,000 bp, with characteristic DNA peaks around 150, 360, 
and 450 bps. 
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???? ??????????????????????????????????????????????????????????? ?????????
????
One of the main aims of this thesis was to characterize the DNA content of prostate 
cancer-derived EV subpopulations and assess their possible relevance as cancer biomarkers, 
since so far, the presence of DNA in EVs has not been deeply investigated. Thus, the DNA 
content of ABs, MVs, and EXOs from LNCaP, PC-3, and RC92a/hTERT prostate cancer cell 
lines and plasma samples from prostate cancer patients and healthy donors were analyzed (I, 
Fig. 4, 5). Specifically, the presence of gDNA fragments of MutL homolog 1 (MLH1), PTEN, 
and TP53 genes and their mutational status was investigated (Figure 8). By conventional 
PCR and qPCR analysis, MLH1 gDNA fragments of 108 bp were detected in all the EV 
subpopulations except RC92a/hTERT EXOs. PTEN gDNA fragments of 225 bp were only 
detected in LNCaP ABs and EXOs, and they contained a frame-shift mutation in the codon 6 
(K6fs*4) by a deletion of two adenines. Additionally, a 316 bp gDNA fragment of the TP53 
gene was confirmed only in LNCaP ABs, which also harbored a polymorphism (P72R) 
detected by the sequencing analysis (Figure 8. A, B). 
 
 
 
Figure 8. Presence of mutated genomic DNA fragments in EV subpopulations. A) Relative ratio 
of genomic DNA (gDNA) fragments of MLH1, PTEN, and TP53 assessed by quantitative PCR (qPCR) 
in LNCaP, PC-3 and RC92a/hTERT EVs using GAPDH as a reference gene. Asterisk (*) represents that 
the gene was not detectable by qPCR or not present in the samples analyzed. Apoptotic bodies (ABs): 
red; microvesicles (MVs): blue, and exosomes (EXOs): green. Bar graphs represent the average value 
of three independent experiments ± SEM. Representative agarose gels of MLH1, PTEN, and TP53 
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gDNA fragments of ABs, MVs, and EXOs from LNCaP, PC-3 and RC92a/hTERT cells. Ladder (L), 
supernatant from the last ultracentrifugation as an internal control (SP), positive control (C+), and 
negative control (C-). B) Chromatograms displaying mutations in PTEN and TP53 fragments in ABs 
and EXOs. The arrows mark the position of the no MLH1 mutation (left), PTEN mutation in codon 6 
(delAA) (center), and TP53 mutation in codon 215 (CCC to CGC) (right). Publication I, Fig. 4. 
 
 
???? ????????????????????????? ???????????????????????????
The mRNA content of MVs and EXOs enriched fractions isolated from LNCaP and PC-3 
prostate cancer cells and benign PNT2 prostate epithelial cells was evaluated for their 
putative use in future clinical diagnosis in prostate cancer. MVs and EXOs derived from 
LNCaP and PC-3 cells were shown to have their own distinct prostate cancer-specific mRNA 
signatures based on their different cellular origin when mRNA transcripts of 84 genes related 
to prostate cancer were analyzed by RT-qPCR -based mRNA arrays (Figure 9).  
 
 
Figure 9. Prostate cancer-derived microvesicles (MVs) and exosomes (EXOs) have unique mRNA 
signatures resembling their parent cells. A) Scatter plots showing a log transformation of the relative 
mRNA level of each gene (2-ΔCt) between: LNCaP MVs (y-axis) and PC-3 MVs (x-axis), and LNCaP 
EXOs (y-axis) and PC-3 EXOs (x-axis). The gray lines indicate a boundary of 10. Genes at prominent 
coordinates are annotated. All data are representative of three independent experiments per group. 
Fold-change cut-off =10. B) Non-supervised hierarchical clustering indicating normalized enrichment 
of the mRNA levels of the most significant genes detected in the LNCaP and PC-3 MVs and EXOs in 
comparison with the PNT2 MVs or PNT2 EXOs. C) Venn diagram representing the statistically 
significant common and unique mRNAs for LNCaP MVs (red) and PC-3 MVs (green) compared with 
PNT2 MVs (Ctrl). The genes displayed in the boxes are common mRNAs for both LNCaP and PC-3 
MVs which are differentially increased or decreased vs Ctrl. Publication II, Fig. 2, 3 and Table 1. 
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MVs and EXOs from LNCaP cells contained characteristic mRNA transcripts of genes 
with documented androgen regulated functions. These include kallikrein-related peptidase 3 
(KLK3), also known as PSA; NK3 Homeobox 1 (NKX3-1) and TMPRSS2, genes related to 
prostate cancer progression; tissue inhibitor of metalloproteinase-3 (TIMP3) and TP53 genes 
(Figure 9. A). On the other hand, in PC3-derived MVs and EXOs, genes reported to be 
associated with advanced and metastatic stages of prostate cancer were detected, including 
mRNAs of glutathione S-transferase pi 1 (GSTP1), caveolin-1 (CAV1), CAV2, cyclin-dependent 
kinase inhibitor 2A (CDKN2A), and TFPI2 (Figure 9. A). A cluster analysis of the gene 
patterns revealed differences in the specific mRNA cargo of EVs (Figure 9. B). This allowed 
the separation of the EVs based on either their benign epithelial or cancer origin. 
Importantly, the mRNAs of the analyzed genes were more abundant in LNCaP and PC-3 cell-
derived MVs compared to EXOs (II, Fig. 3), and all the transcripts present in EXOs were also 
found in MVs.  
To evaluate the usability of the mRNA content of LNCaP and PC-3 cell-derived MVs in 
the prediction of the cancerous status of the parent cells, the mRNA transcripts of prostate 
cancer-derived MVs were compared with the mRNAs of the benign control PNT2 MVs 
(Figure 9. C). Around 55.8% of the mRNAs were found to be common across the samples, 
whereas 44.2% were unique. Sixteen mRNAs from LNCaP MVs and 32 mRNAs from PC-3 
MVs, were statistically significantly different from mRNAs in PNT2 MVs. From the analysis 
of the statistical changes in the mRNA abundance and the overlap between the normalized 
samples, eight mRNAs were found to be unique for LNCaP MVs [increased (CDH1, NKX3-1, 
TMPRSS2, TP53), decreased (CAV1, GSTP1, SOCS3, TFPI2)], and 17 for PC-3 MVs [increased 
(CAMSAP1, CAV1, CAV2, GSTP1, NRIP1, PES1, TFPI2, ZNF185), decreased (AR, EGR3, IGF1, 
PTEN, RARB, SFRP1, SLC5A8, TMPRSS2, TNFRSF10D)] (II, Fig. 4 or Supplementary 
Tables 2-3). 
After determining the genes with statistically significant mRNA levels in prostate 
cancer MVs compared to the non-cancer MVs, the common mRNAs for both LNCaP and PC-
3 MVs were determined. Increased mRNA levels of several genes were detected, including: 
Ets variant 1 (ETV1), a gene that directs androgen metabolism and confers aggressive 
prostate cancer; FASN, a fatty acid metabolism gene highly up-regulated in prostate cancer; 
and RNA binding protein 39 (RBM39), a gene implicated in cancer progression. On the other 
hand, a decrease in the mRNA levels in prostate cancer MVs of genes such as cyclin D2 
(CCND2), a crucial cell cycle-regulatory gene down-regulated in prostate cancer cells and the 
transcription factor ERG, were observed (II, Table 1). These results were compared with 
studies based on microarray analysis of EV-associated mRNAs collected in the EVpedia 
database. The common mRNAs identified in prostate cancer MVs were compared with the 
same mRNAs reported in EVs from different sources (II, Fig. 5). With the exception of FASN 
mRNAs, which were detected in 6 out of 10 studies, few reports found the studied mRNAs, 
and none of them in prostate cancer EVs. Finally, the common mRNAs detected in prostate 
cancer MVs were compared with the clinical microarray datasets of benign and malignant 
prostate tissues publically available in the GEO database (GSE55945). Some of the mRNAs 
discovered in prostate cancer MVs, including ETV1 and FASN genes, were shown to be 
differentially over-expressed in malignant prostate tissues in comparison to benign controls 
(II, Fig. 5). 
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???? ???????????????????????????????????????????????????????????????
???????????????????????????????????????????????
Next, the differences in the internalization and functional effects of prostate EVs and 
their contribution to cancer progression were analyzed. MVs and EXOs from various prostate 
cell lines of metastatic (PC-3 and LNCaP cells), primary (RC92a/hTERT cells), and benign 
(PNT2 cells) origin were compared to study how the cancer status of the parent cell affected 
the EV uptake. 
EV internalization was shown to be an active process dependent on both temperature 
and EV concentration. EV uptake was disrupted by incubation of the samples at 4°C, and an 
EV concentration of 109 particles/mL was found to be the optimal vesicle amount to study EV 
uptake by flow cytometry (III, Fig. 1). To test whether cancer and non-cancer cells could 
differentially internalize EVs, the amount of cells containing EVs at several time points was 
analyzed by three different approaches; an automated microscopic imaging system, confocal 
microscopy, and flow cytometry (Figure 10). EV uptake began immediately after the EV 
addition and continued at least up to 24 h in a time-dependent manner (III, Fig. 2, 3; IV, 
Fig. 3). The uptake of metastatic site-derived EVs (PC-3, LNCaP) was clearly more efficient 
than the uptake of EVs from benign or primary cancer cells (PNT2, RC92a/hTERT). This 
phenomenon was detected both in the benign and metastatic recipient cells (PNT2 and PC-3) 
(III, Fig. 2). No statistically differences in the internalization kinetics were found between 
MVs and EXOs (III, Fig. 2; IV, Fig. 3). Consequently, MVs and EXOs were combined as a 
total EV pool to further analyze the differences between the EVs based on their origin. 
 
 
 
Figure 10. Uptake kinetics and internalization of prostate cancer cell-derived EVs. EVs isolated 
from prostate cancer cell lines of metastatic origin (PC-3 and LNCaP); a primary prostate cancer cell 
line (RC92a/hTERT); and normal prostate epithelial cells (PNT2) were incubated with cancer and 
non-cancer cells. A, B) EV internalization analysis was performed by flow cytometry in PC-3 cells and 
PNT2 cells. Results are plotted as normalized geometric mean of fluorescent intensity (gMFI) of EV 
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fluorescence in cells. Bars represent mean ± SEM of three independent experiments per group. *P 
<0.05, **P <0.01, ***P <0.001, ****P <0.0001, two-way ANOVA with Tukey's multiple comparisons 
test. C, D) Representative confocal images depicting internalization of DiIC18(5)-DS-labeled EVs 
(pseudo-colored green) by PC-3 and PNT2 cells (CD44 plasma membrane marker pseudo-colored red 
and nuclei colored blue). 3D projections of z-stacks are also shown. Scale bars, 5 μm. Publication III, 
Fig. 3. 
 
 
Additionally, when the uptake efficiency of EVs of cancer and non-cancer origin was 
compared using flow cytometry, a similar trend for EV uptake kinetics was observed in both 
cell types. Metastatic site-derived PC-3 and LNCaP EVs were overall more efficiently 
internalized than EVs derived from RC92a/TERT prostate cancer primary cells, or from 
PNT2 benign prostate epithelial cells by PC-3 cells after 9 h and 12 h incubations (Figure 10. 
A). The benign PNT2 cells significantly internalized PC-3 and LNCaP EVs as well as PNT2 
EVs after 9 h and 12 h, but almost no RC92a/hTERT EV internalization was observed 
(Figure 10. B). Overall, no significant differences in the total EV uptake between the cells 
was observed (III, Fig. 3). Confocal microscopy analysis confirmed the intracellular presence 
of EVs in both PNT2 and PC-3 cells (Figure 10. C, D). Independently of the EV 
subpopulation analyzed, the majority of the EVs were inside the cells and not only adhering 
to the cell surface, as depicted by the low 5% co-localization of labeled EVs with the cellular 
plasma membrane (III, Fig. 4). Moreover, around 30% of the EVs co-localized with the 
endolysosomal compartments (III, Fig. 4), suggesting that EV internalization process may 
occur through endocytosis. PNT2 EVs co-localized significantly more with early endosomes 
compared to PC-3 EVs, which was in line with the slower uptake of PNT2 EVs (III, Fig. 3). 
No other significant differences were detected in the co-localization of cancer vs non-cancer 
derived EVs with the cell organelles. Since EVs can also have protein motifs on their surface 
that could be used to mimic a possible targeted delivery to their autologous cells, the effect of 
the removal of the membrane surface proteins of EVs on the overall vesicle uptake was also 
assessed. Trypsin treatment did not alter the uptake of EXOs. However, after 24 h 
incubation, a decrease could be observed in the internalization of trypsin-treated MVs (IV, 
Fig. 3).  
High-resolution confocal microscopy images showed that EV internalization was not a 
constant and uniform process for all cells cultured under the same conditions (Figure 11. 
9A). When the labeled EVs were added to the cells, some of them internalized the EVs 
whereas other cells did not. Therefore, the influence of the cellular phase [resting phase/Gap1 
(G0/G1), DNA synthesis (S), and Gap2 (G2) and mitosis (M)] on EV internalization was 
addressed by using PC-3 cells incubated with LNCaP EVs. Although a trend of increased EV 
uptake of cells in G2/M compared to G0/G1 or S phases was observed, no significant 
differences in the cell cycle phases were shown for the total EV population at the early time 
points. Interestingly, after 24 h and 48 h incubation with the EVs, a statistically significant 
increase in the EV concentration was observed in cells that were in G2/M phase (III, Fig. 5). 
Results also showed that EV uptake did not increase the total amount of cells in G2/M phase 
(III, Fig. 5). When MVs and EXOs were incubated separately, PC-3 cells in G2/M phase 
displayed a significantly higher MV count already evident after 3 h and 6 h incubation 
compared to cells in S or G0/G1 phases. The cellular concentration of EVs could be roughly 
classified according to the cell cycle phase G2/M > S > G0/G1 (III, Fig. 5).  
The ability of prostate-derived EVs to promote functional changes in recipient cells was 
next evaluated. The proliferation of cancer and non-cancer cells was analyzed after 
incubation with EVs derived from LNCaP, PC-3, RC92a/hTERT, and PNT2 cells (III, Fig. 6). 
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For PC-3 cells (with a doubling time of approx. 38 h), an increase in proliferation of the EV-
treated cells in comparison to the control became statistically significant only after 72 h 
incubation. 
 
 
Figure 11. Metastatic EVs promote cellular proliferation and migration of prostate cells. A) PC-
3 cells were incubated for 12 h with DiIC18(5)-DS EVs (pseudo-colored green) and cells were 
immunostained with CD44 for plasma membrane (red) and DAPI for nuclei (blue). Scale bars 20 μm. 
Proliferation of B) PC-3 cells and C) PNT2 cells after 72 h incubation with EVs derived from PC-3, 
LNCaP, RC92a/hTERT, and PNT2 cells or without (wo) EVs. Cellular proliferation was measured by 
flow cytometry using CFSE label. The results are presented as the Log10 of the relative CFSE geometric 
mean fluorescent intensity (gMFI). Small or negative values indicate less CFSE label and consequently 
more cellular proliferation. Bars are mean ± SEM of three independent experiments per group. *P 
<0.05, **P <0.01, ***P <0.001, ****P <0.0001, one-way ANOVA with Tukey's multiple comparisons 
test. D) PC-3 cell migration was monitored during the incubation with EVs for up to 6 h. Graph 
showing the percentage (%) of total migration of PC-3 cells after addition of EVs or control without 
(wo) EVs. Error bars are mean ± SEM of six independent experiments per group. *P <0.05, **P <0.01, 
one-way ANOVA with Dunnett's multiple comparisons test. Publication III, Fig. 6. 
 
 
All the EVs increased the cellular proliferation of PC-3 cells (Figure 11. B). However, 
the metastatic PC-3 EVs increased the cell proliferation significantly more than the other EV 
types. When PC-3 cell-derived MVs and EXOs were compared for their capacity to enhance 
cell viability, EXOs had a stronger viability enhancing effect than MVs, although both 
subpopulations enhanced cell viability (IV, Fig. 4). The effect was EV concentration 
dependent, achieving an enhanced effect with 108 particles/mL or higher concentrations. In 
contrast, an EV-induced increase of the proliferation of the benign slow-growing PNT2 cells 
was already apparent after 48 h incubation (III, Fig. 6). EVs from both cells of metastatic 
origin showed increased PNT2 cell proliferation compared to the primary and benign cell-
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derived EVs. This effect became more notable after 72 h incubation, with PC-3 EVs 
significantly increasing the cell growth compared to the other EVs and control (Figure 11. 
C). Remarkably, PNT2 EVs did not induce proliferation of PNT2 cells, but showed a slight 
growth reduction compared to the control. All prostate cancer cell-derived EVs, including 
primary and metastatic EVs, significantly enhanced migration of PC-3 prostate cancer cells, 
whereas EVs isolated from benign cells had no effect (Figure 11. D). Overall, the EV 
internalization efficiency and stimulation of malignant transition in recipient cells could be 
classified according to the metastatic potential of the EV parent cells PC-3 > LNCaP > 
RC92a/hTERT > PNT2. 
 
 
???? ???????????????????????????????????????????????????????????????????????????
To evaluate the usability of EV subpopulations as drug delivery vehicles, LNCaP and 
PC-3 MVs and EXOs were tested in the in vitro delivery of paclitaxel, a pharmacological 
antimitotic cancer drug. Here, cancer-derived EVs were used as a proof of concept model for 
autologous cancer treatment, since cancer cell-derived EVs were efficiently internalized by 
cells as proven above (Figure 10). EVs were loaded by passive diffusion since paclitaxel is a 
small and highly hydrophobic drug with a log P value of 3.96 and an aqueous solubility of less 
than 0.01 mg/mL (Surapaneni et al., 2012). By using 5 μM paclitaxel, the average loading 
efficiency of MVs and EXOs, independent of the particle concentration, was around 10.3% 
and 7.5%, respectively (IV, Table 1), with no apparent release of paclitaxel from EVs to the 
media after 24 h and 48 h in the study.  
 
 
 Figure 12. Enhanced cytotoxic effect of EV-mediated delivery of paclitaxel. Cell viability 
experiments were conducted to analyze the effect of free 5 μM paclitaxel (free PtX) and paclitaxel-
loaded EVs (PtX-EVs) in prostate cancer cells. A) PC-3 cells were incubated with different 
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concentrations of paclitaxel-loaded microvesicles (PtX-MVs) and paclitaxel-loaded exosomes (PtX-
EXOs) during 48 h to establish the dose-dependency effect of the PtX-EVs. MVs and EXOs were 
loaded with 1 nmol of PtX per 109 vesicles and dilution series were established to evaluate the dose 
dependency of PtX-EVs. Bars are mean ± SEM of three independent experiments per group. B) Overall 
comparison of the cytotoxic effect of the different concentrations of PtX-MVs and PtX-EXOs which 
had a cytotoxic effect in PC-3 cells after 48 h incubation. Bars represent mean ± SEM of four 
independent experiments per group. *P <0.05, unpaired t test. C) Cytotoxic effect of MVs and EXOs 
loaded with 5 nmol PtX per 108 vesicles at 24 h, 48 h, and 72 h. Bars represent mean ± SEM of five 
independent experiments per group. *P <0.05, **P <0.01, two-way ANOVA with Dunnett´s multiple 
comparison test. The presented results are re-analysis of publication IV, Fig. 5. 
 
 
 Paclitaxel-loaded MVs had a stronger cytotoxic effect than paclitaxel-loaded EXOs, 
reducing the viability of PC-3 cells regardless of the EV concentration used (Figure 12. A). A 
possible saturation point for paclitaxel-loaded MVs and EXOs was apparent at around 109 
particles/mL, at which point the maximal cytotoxic effect of paclitaxel-loaded EVs was 
observed. When the overall cytotoxic effects of concentrations of paclitaxel-loaded MVs and 
EXOs below the saturation point were compared, MVs had a statistically significant cytotoxic 
effect compared to EXOs, reducing the viability of cells by 60% after 48 h incubation (Figure 
12. B). Lower concentrations of EVs loaded with the same amount of drug, corresponding to 
a ratio of paclitaxel/EV 50 times higher than in the previous settings, induced a statistically 
significant increase in the cytotoxicity of both paclitaxel-loaded MVs and EXOs compared 
with the free drug (5 μM) after 48 h and 72 h (Figure 12. C). These results indicate that the 
combination of high amounts of paclitaxel per vesicle and a number of EVs below the 
saturation point produce the maximum cytotoxic effect.  
  
 
Figure 13. Internalization of paclitaxel (PtX) and DiD-labeled EVs by prostate cancer cells. 
LNCaP cells were incubated during 24 h with A) DiD-labeled EVs (red), B) Free 5 μM PtX (green), C) 
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PtX-loaded DiD-labeled EVs, and D) combination of free PtX and DiD-labeled EVs. Representative 
images are shown. Scale bars 10 μm. Publication IV, Fig. 7. 
 
 The increased cytotoxic effect of paclitaxel-loaded EVs was not caused by the presence 
of free paclitaxel in solution, since no detectable leaking of paclitaxel was detected, and 
incubation of cells with a combination of free drug and EVs resulted in a lag, but not 
enhanced, cytotoxic effect of paclitaxel (IV. Fig. S2).  
 In further analysis of the effect of paclitaxel-loaded EVs in LNCaP and PC-3 cancer 
cells, an overlap in the labeled EVs and the fluorescent paclitaxel showed that drug was 
delivered to the cells via EVs (IV, Fig. 6, 7). While the internalization of DiD-labeled EVs did 
not have any negative effect in terms of the cell viability (Figure 13. A), the incubation of 
prostate cancer cells with free 5 μM paclitaxel caused cell shrikage and death (Figure 13. B). 
When paclitaxel was delivered to the cells by EVs, drug/EV complexes were internalized by 
the cells through endocytosis, as shown by the co-localization of the labeled EVs with 
lysosomes (IV, Fig. 6). In the endosomal network, the fluorescent paclitaxel seemed to 
separate from the EV-label, binding to the microtubules and eventually spreading within the 
cell causing death (IV, Fig. 7) (Figure 13. C). The EV-mediated effect was similar to that of 
the free paclitaxel, albeit weaker most likely due to the smaller amount of paclitaxel. Finally, 
free paclitaxel was added to the cells together with the DiD-labeled EVs without the drug 
(Figure 13. C). Cells that internalized notable amount of EVs were still alive after 24 h 
incubation, counteracting the effect of free paclitaxel. Although EVs were not loaded with 
paclitaxel, the drug could partially bind EVs in the cell media due to its high hydrophobicity, 
as could be qualitatively shown by the co-localization of paclitaxel with the endolysosomal 
cell compartment. 
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???? ???????????????????????????????????????????????????????????????
???????????
When it comes to treating cancer, a more specific diagnosis is needed to identify the 
presence of tumors in early stages, increasing the number of treatment options. New non-
invasive and more efficient sources of biomarkers are required to stratify patients harboring 
e.g., different stages of prostate cancer. The discovery that the content of EVs is tissue/cell-
specific has underlined a particular interest in the use of EVs as a potential source of cancer 
biomarkers. One of the primary aims of this thesis was to assess the nucleic acid cargo of EVs 
as a possible source of prostate cancer biomarkers, particularly the gDNA content 
(publication I) and mRNA content (publication II) of different EV subpopulations.  
The RNA cargo of EVs has been widely investigated in cancer. miRNAs have attracted 
the most attention, while far fewer studies have evaluated the use of EV-associated mRNAs as 
a possible source of biomarkers (Table I). In contrast to RNA, EV-associated DNA 
represents a more unexplored source of information that, in the context of prostate cancer, 
was first discovered in prostasomes (Ronquist et al., 2012; Ronquist et al., 2009). The results 
presented in this thesis showed that, despite the notable overlap in size distribution and 
protein markers of the different EV subpopulations obtained by differential centrifugations, 
prostate cell-derived EV subpopulations had distinct DNA and RNA contents (Figure 7). 
DNA fragments were first found in ABs, which was an expected finding, as during cell death 
by apoptosis DNA is cleaved into different sized fragments and secreted to the extracellular 
space, partly associated to apoptotic blebs as previously shown (Halicka et al., 2000; 
Holmgren et al., 1999; Schiller et al., 2008). ABs and MVs were also enriched in rRNA, with 
relatively low amounts of small RNA molecules, as also described in ABs and MVs from the 
mast, erythroleukemic, and melanoma cell lines (Crescitelli et al., 2013; Lunavat et al., 2015; 
Willms et al., 2016). On the other hand, EXOs contained increased amounts of DNA 
compared to other EVs, and mainly small RNA molecules within their cargo. The same RNA 
pattern has previously been observed in EXOs from other cellular sources (Crescitelli et al., 
2013; Lunavat et al., 2015; Willms et al., 2016), but in some of these studies, EXOs were also 
shown to contain a broad spectrum of fragmented and intact RNA molecules, including 
mRNAs, miRNAs, and other ncRNA species (Ahmed et al., 2014; Bellingham et al., 2012; 
Lunavat et al., 2015; Nolte-'t Hoen et al., 2012; Vojtech et al., 2014). It is also plausible that 
certain RNAs detected in our study might be located outside the EV lumen associated with 
the outer membrane. Currently, the use of RNAse treatment prior to RNA extraction of EVs is 
rather controversial. The enzymatic treatment would be of benefit, as it will remove all 
possible RNA contaminants from cell lysis, allowing the analysis of the RNA molecules within 
EVs. However, RNAses can be extremely difficult to dose and difficult to inactivate, which 
could compromise the integrity of the RNA in the EVs. For instance, no major differences 
were reported in the total RNA content of ABs, MVs, and EXOs enriched fractions before and 
after RNAse treatment (Lunavat et al., 2015), indicating that EVs confer a certain degree of 
RNA protection. On the other hand, EXOs had a variable amount of DNA, with different 
length DNA molecules identified in both prostate cancer cell line derived- and plasma-
derived EXOs after DNAse treatment. Similar results have also been shown in other cancer 
cell-derived and plasma-derived EXOs, with protected DNA fragments ranging from 100 bp 
to 17 kbp after enzymatic treatment (Cai et al., 2013; Kahlert et al., 2014; Thakur et al., 2014). 
Interestingly, the DNA profile traces of prostate cancer EXOs suggest substantial 
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fragmentation of the EXO-DNA (Figure 7). The pattern of DNA size in EXOs was found to 
be similar to that of the DNA wrapped around histone proteins (Olins and Olins, 2003). 
Therefore, we hypothesize that the DNA found in EXOs may partly be protected from 
degradation by histone proteins either inside the vesicles or in association with them. 
Although different DNA and RNA content in prostate cancer EV subpopulations was 
shown by these studies, improvements in the EV isolation and characterization will 
contribute to a better understanding of the variability of EVs in isolates. Currently, there are 
no methods that allow the exact separation of EV subpopulations (Witwer et al., 2013). New 
isolation procedures including affinity-based isolations e.g., microfluidic devices, 
photosensitizer, and immunomagnetic beads (Im et al., 2014; Jørgensen et al., 2013; Kanwar 
et al., 2014; Kim et al., 2012a; Tauro et al., 2012), size-based isolations e.g., acoustic waves 
and micro pillar-based methods (Lee et al., 2015b; Santana et al., 2014; Wang et al., 2013), 
and novel characterization techniques as Raman spectroscopy (Smith et al., 2015; Stremersch 
et al., 2016b), Surface Plasmon Resonance (Rupert et al., 2014; Suutari et al., 2016; Zhu et 
al., 2014), and new generation flow cytometers fine-tuned to measure particles below 400 nm 
(Headland et al., 2014; Pol et al., 2014), will contribute to a deeper characterization of more 
“pure” EV subpopulations. The implementation of these techniques in combination with 
genomics, transcriptomics, proteomics, and metabolomics of specific EV subsets will allow a 
broader perspective of the utility and functional relevance of the unique cargo responsible for 
driving cancer progression. 
 
 
?????? ?????????????????????????????
EV-associated DNA may hold remarkable value in clinical diagnostics as candidate for 
cancer biomarkers, since it can provide information about the characteristics of the tumors, 
including their mutation pattern. The results presented in the first study aimed to determine 
the gDNA content of prostate cancer-derived EVs and its utility to evaluate mutations 
(publication I). 
The presence of mutated gDNA fragments of MLH1, PTEN, and TP53 genes was 
confirmed in ABs and EXOs isolated from prostate cancer cell lines (Figure 8). The presence 
of mutated DNA content within EVs from pancreatic cancer, melanoma, and lung cancer 
origin was simultaneously reported by others (Kahlert et al., 2014; Lee et al., 2014; Thakur et 
al., 2014). The detection of oncogenic mutations in EVs from different origins, including RAS, 
BRAF, and EGFR genes, was in line with our findings in prostate cancer cell-derived EVs. 
The fact that gDNA is found in EVs reflecting the mutational status of the parent tumor cells 
supports the concept of EV-associated DNA as a new effluent biomarker type. By secreting 
EVs, part of the gDNA content of the cells can be specifically circulated as protected DNA, 
which might contribute to genomic instability as a result of the functional transfer of 
oncogenic sequences, as previously reported for ABs (Bergsmedh et al., 2001), and also to the 
preparation of the pre-metastatic niche of the tumors. However, it is far from clear if the 
protected DNA from prostate cancer cell line-derived EVs represents the whole genome, as 
previously claimed by the genome sequencing analyses of other EV subtypes (Kahlert et al., 
2014; Lee et al., 2014; Ronquist et al., 2009; Thakur et al., 2014) or if the cells can specifically 
pack certain kinds of DNA in vesicles, such as mtDNA (Guescini et al., 2010), for instance 
during the advanced stages of prostate cancer. Moreover, what the function of this DNA is 
and how it is packed into the EVs remains unclear.  
In the prostate cancer field, this study was the first to show that double-stranded gDNA 
molecules were detected in EVs isolated from plasma samples of prostate cancer patients. 
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Prostate cancer patients showed an increased number of EVs compared to healthy controls. 
Increased EV concentrations in the systemic circulation of patients with other cancers have 
also been reported, with an estimated 4,000 trillion EVs in the blood circulation, which is 
approximately double the number found in blood from healthy individuals (Kalluri, 2016). 
However, none of the mutations present in the cell line-derived EVs could be detected in the 
plasma EVs from the patient cohort analyzed. This could be due to the too small number of 
cancer-originating EVs in the diverse collection of EVs in the circulation, or due to the 
absence of these mutations in these small patient cohort. In future studies, the analysis of 
bigger patient cohorts and the use of tissue- or cancer-specific markers to enrich the number 
of cancer EVs from the heterogeneous EV pool, as shown by immunoaffinity capture of colon 
cancer A33-EXOs and EpCAM-EXOs (Tauro et al., 2013), could increase the probability of 
detecting oncogenic mutations. Moreover, patient’s tumor biopsies should be analyzed in 
order to validate the presence or absence of the mutations found in EVs. The use of more 
sensitive methods such as co-amplification-at-lower denaturation-temperature PCR, which 
selectively amplifies and identifies minority alleles and low-level somatic mutations, will 
surely contribute to the identification of EV-associated oncogenic sequences reflecting the 
original tumors as recently shown (García-Romero et al., 2016).  
The comparison between cell lines and patient’s plasma samples from the same disease 
model puts in perspective cell lines as a mimic of pure cancer cell populations, limiting the 
translation of the results to in vivo settings. While established cancer cell lines generate a 
wide diversity of EV subsets arising from the same cell type, plasma from cancer patients is 
heterogeneous, where EVs from many different sources, both from cancer and all normal 
cells, including immune cells, co-exist. This is likely one of the reasons why biomarker 
discovery with EVs isolated from biofluids is most challenging, and why it is relevant to 
isolate and study the correct type of EVs as the source of biomarkers. Additionally, no 
biomarker based on EV analysis has yet been realized, partially due to the lack of 
standardization and reference materials (Valkonen et al., 2016), which complicates the 
analysis of the EVs and the comparison of results between patients.  
Clearly, studying the mutation signature of DNA in the prostate cancer EVs and 
correlating these findings with clinical parameters of the individual patients, including the 
tumor stage, PSA levels, and treatment response, could contribute to an earlier diagnosis of 
the disease and maybe even help to further tailor specific treatments for prostate cancer 
patients.  
 
 
?????? ???????????????????????????????????????????????????????
RNA signatures of EVs have been reported to be specific for their cells of origin, 
discriminating, for instance, the transformation status of cancer cells (Ahadi et al., 2016; 
Jenjaroenpun et al., 2013). In the second study of this thesis, mRNA transcripts of genes 
known to be involved in prostate cancer were identified in prostate cancer cell-derived MVs 
and EXOs from LNCaP and PC-3 cells (publication II), the two major prostate cancer cell 
models for low and high metastatic potential, respectively (Dozmorov et al., 2009). The 
results showed that MVs rather than EXOs were enriched in the mRNAs analyzed by RT-
qPCR. Based on these findings, MVs rather than EXOs would represent the optimal EV 
subpopulation for biomarker mining. Since most of the EVs in the MV population are usually 
larger than the majority of EVs in the EXO population, they might be able to carry more 
bioactive molecules, including mRNAs. So far, the EV field has held the EXOs in superior 
position as cancer biomarker discovery (An et al., 2015; Kalluri, 2016), which makes this a 
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significant observation. Other than in thrombosis and hemostasis, where microparticles have 
been extensively studied (Aatonen et al., 2012), the advantageous properties of the larger 
vesicles have been less explored, and only a few studies have focused on larger cancer 
vesicles, such as LOs (Minciacchi et al., 2015). Additionally, it is postulated that EV contents 
are not randomly packed, raising the possibility of selective export of certain molecules 
within EVs (Yáñez-Mó, Siljander et al., 2015). This cargo specificity was shown by the 
presence of certain miRNAs within EXOs and their absence in the parent tumor cells (Nolte-
't Hoen et al., 2012; Ohshima et al., 2010; Zhang et al., 2010). When prostate cancer EVs 
were analyzed, the RNA profile of MVs resembled more the RNA profile of the parent cells 
compared to EXOs, thereby providing a more accurate snapshot of the tumor cell 
transcriptome. Additionally, the unique mRNA signatures of LNCaP and PC-3 MVs 
facilitated the distinction of the characteristics of their parent cells. MVs and EXOs from 
androgen sensitive LNCaP cells contained characteristic mRNA transcripts of genes with 
documented androgen regulated functions, including for instance TMPRSS2, previously 
identified as a fusion gene TMPRSS2-ERG in EVs isolated from prostate cancer cells and 
urine from prostate cancer patients (Dijkstra et al., 2014; Jansen et al., 2009; Nilsson et al., 
2009). On the other hand, the majority of the mRNAs associated with PC-3 MVs were related 
to advanced and metastatic stages of the prostate cancer (Jarrard et al., 1997; Meiers et al., 
2009; Yang et al., 1999), as reflected by the high metastatic potential of PC-3 cells (Dozmorov 
et al., 2009). This argues that different cancer cell lines from the same cancer type, such as 
prostate cancer, can release an EV secretome carrying essentially different RNA molecules. It 
also proves that the features of the parent cells can be detected and analyzed within MVs, 
supporting the concept of liquid biopsy analysis of circulating EVs (Moon et al., 2016; 
Yoshioka et al., 2014). However, the possibility that some of the EV-associated RNA 
molecules were adsorbed to EVs cannot be excluded, complicating the comparison of the 
relative amount of EV-associated RNAs among cell lines. This is of particular importance 
when trying to compare EV-associated RNAs from different cellular sources as cancer-
specific biomarkers. To reduce this possibility and to avoid considering subtle differences, a 
high fold-change threshold limit was chosen in order to study the significant changes in the 
EV-associated mRNAs. 
The common mRNAs for both LNCaP and PC-3 prostate cancer MVs were first 
identified in our study, and only a few reports have examined the presence of mRNA 
transcripts of these genes in other cancer-derived EVs (Kim et al., 2015). Another interesting 
finding was the possible clinical relevance of the candidate mRNAs. Comparative analysis of 
these mRNAs with a publically available datasets of mRNAs from malignant and benign 
prostate tissue samples showed the over-expression of e.g., ETV1 and FASN mRNAs in 
patient samples, which were also abundant in the prostate cancer EVs. In future studies, a 
validation of these results from EVs isolated from blood or urine of prostate cancer patients 
compared to patients with benign prostate hyperplasia will elucidate the significance of these 
findings and their utility in future biomarker research.  
Furthermore, we also believe that a good candidate marker should be based on the 
expression ratio of mRNA transcripts of several genes dysregulated in cancer rather than on 
the expression of a single gene. The use of mRNAs of genes that are differentially increased 
and decreased in prostate cancer-derived EV samples compared to controls would be rather 
more informative, as proposed by the results of this study. Overall, these findings indicate 
that the MV-associated mRNAs could be of potential use to assess disease progression, 
highlighting the possible relevance of examining the mRNA cargo in MVs as a partial 
representation of the tumor transcriptome.  
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Together, presented studies (publication I and II) provide further insights into the 
proportion of cell genome and transcriptome that can be identified in EVs and highlight the 
relevance of the nucleic acid cargo of EVs in cancer diagnostics. The different cargo 
characteristics of the analyzed EV subpopulations demonstrate that EVs represent the 
dynamic changes in the tumor and its progression. Based on the presented results, the 
combination of DNA and RNA analysis from EVs is also suggested as a more robust and 
sensitive cancer biomarker.  
 
 
???? ???????????????????????????????????????????????????????????????????????
In cancer, EVs facilitate tumor progression by supplying biomolecules to the tumor 
niche in support of oncogenic processes towards tumor development and dissemination 
(Figure 4). Based on that, the next point addressed in this thesis was the evaluation of the 
role of prostate cancer cell-derived EVs in cell-to-cell communication (publication III). 
 
 
?????? ???????????????????????????????????????????????????
To efficiently deliver their cargo, EVs can either fuse with the plasma membrane or be 
internalized as intact EVs by the cells. The studies presented in the thesis (publication III 
and IV) compared the uptake efficiencies and the effects on the internalization of different 
EVs on prostate cancer and benign cells. Results showed that EV uptake by cancer and non-
cancer cells was a constant and active process as previously reported (Christianson et al., 
2013; Feng et al., 2010; Svensson et al., 2013). No apparent differences were shown in the 
overall internalization kinetics of MVs and EXOs when subpopulations were compared. This 
was a relevant finding, since the vast majority of the studies investigating the role of EVs in 
intercellular communication have not compared the different EV subsets (Mulcahy et al., 
2014), and only a few reports so far have depicted the differential roles of MVs and EXOs e.g., 
in HIV-1 infection (Kadiu et al., 2012). Importantly, prostate cancer and non-cancer cells 
internalized EVs with similar efficiencies. Several studies have reported changes in the EV 
uptake based on the phagocytic or non-phagocytic status of the EV acceptor cells and their 
cancer or non-cancerous origin (Feng et al., 2010; Rana et al., 2012). Interestingly, in 
publication III, metastatic site-derived EVs were more efficiently internalized than those 
from benign or primary malignant cells (Figure 10). The co-localization of EVs with 
endolysosomal compartments supports the evidence that EVs are preferentially internalized 
through endocytosis, in agreement with other reports (Escrevente et al., 2011; Nanbo et al., 
2013; Svensson et al., 2013). However, the possible fusion of EVs with the plasma membrane 
cannot be excluded. Higher co-localization of PNT2 EVs with the early endosomes as 
compared to PC-3 EVs is likely to reflect the slower uptake of non-cancer vesicles. However, 
the faster internalization kinetics and intercellular trafficking of cancer EVs may depend, for 
instance, on the specific protein-to-protein interactions between EVs and acceptor cells, as 
speculated by other groups (Christianson et al., 2013; Raposo et al., 1996; Svensson et al., 
2013). The enzymatic treatment of EVs with proteinase K to remove EV surface protein was 
shown to reduce the uptake of EVs by ovarian cancer cells (Escrevente et al., 2011). The 
uptake efficiency of EXOs after protein removal was not altered for the present study, but a 
decrease in the MV internalization was apparent for trypsin treated MVs (publication IV). 
However, besides membrane proteins, other EV components such as lipid rafts may also have 
a relevant role in the EV uptake (Svensson et al., 2013). Several studies evidenced the 
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participation of lipid raft-associated proteins in EV uptake, such as e.g., caveolin and 
flotillins, supporting the hypothesis that lipid rafts are partly involved in the EV 
internalization mechanism (Mulcahy et al., 2014). Additionally, certain pathways like 
macropinocytosis may not require any specific interaction between the EVs and cells (Nakase 
et al., 2015), and could simultaneously occur with other internalization routes when the cell 
recognizes specific EV subsets. Although exciting, these observations must be interpreted 
cautiously. Despite the fact that confocal microscopy analysis evidenced EV internalization 
and co-localization with cellular organelles (Figure 10) (III, Fig. 3, 4), lipophilic dyes cannot 
be used for long-term tracking of the EV cargo. New labeling strategies such as fluorescently 
tagged molecules bound to the EV-membrane proteins or lipids have to be implemented to 
track the delivery of the EV cargo while EVs are trafficking in the cells. 
The cell cycle analysis performed in this study showed that prostate cancer cells 
internalized EVs more efficiently during G2/M phases (III, Fig. 5). To our knowledge, this is 
the first time that the influence of cell cycle on EV uptake has been described. These results 
are consistent with a previous finding examining the role of cell cycle in the cellular uptake of 
synthetic nanoparticles (Kim et al., 2012b). This study revealed an increased concentration of 
nanoparticles when cells are in G2/M, in support of the results presented in publication III. 
However, the possibility that the higher EV counts in the mitotic cells were due to the 
stimulation of mitosis by the EVs cannot be excluded, since cancer EVs support cell viability 
and proliferation, as demonstrated in publications III and IV and also shown by others 
(Haga et al., 2015; Lindoso et al., 2015; O’Brien et al., 2013; Yang et al., 2013). However, a 
trend of higher EV counts in the mitotic cells was already apparent after a short incubation (3 
h to 6 h), when the cells had not had sufficient time to proliferate, indicating that EVs might 
promote cell division.  
Enhanced EV uptake by actively dividing cancer cells could also stimulate cancer cell 
spreading. For this reason, the ability of prostate-derived EVs to induce functional changes in 
the recipient cells was evaluated. In contrast to prostate benign and primary malignant cells, 
metastatic site-derived EVs promoted a more proliferative and migratory behavior in the 
recipient cancer and non-cancerous cells. Other reports have also demonstrated that 
malignant metastatic and non-metastatic cell line-derived EVs induced a differential 
complement activation and markedly reduced stiffness and adhesion in recipient cells 
compared to non-malignant cell line-derived EVs (Whitehead et al., 2015). Metastatic breast 
cancer cells also secreted EVs with distinct protein signatures, which increased cancer cell 
movement (Harris et al., 2015), complementing these results. However, the proof that the 
increase in prostate cancer cell proliferation and migration was related to the metastatic 
potential of the parent cells of EVs was first demonstrated in this study. These findings also 
support the concept that EVs derived from cells of metastatic origin harbor the potential to 
support the malignant transition in recipient cells (Figure 11). Remarkably, PNT2 EVs did 
not induce proliferation of PNT2 cells, but slightly showed a growth reduction compared to 
the control and other EV treatments. This feature of non-malignant EVs could be of 
advantage for instance in the delivery of therapeutic molecules.  
Despite the extensive research on intercellular communication, the role of EVs in 
cellular signaling has only started to become clear. Overall, the results presented here 
strongly support the hypothesis that prostate cancer EVs have an active role in stimulating 
cancer progression and malignization compared to non-malignant cell-derived EVs. 
However, considering the importance of EV-mediated cellular communication and the 
limited knowledge available regarding the molecular mechanisms that drive those changes, it 
is highly relevant to investigate the differences in the EV characteristics and cargo to 
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understand their role in heterogeneous cancers. The study of disease-promoting EV, as well 
as the current mechanisms of EV internalization into cells, could reveal new ways to 
specifically target diseases by blocking communication between healthy and disease tissues. 
In addition, analysis of the uptake kinetics of different EVs may help to select the most 
appropriate EV source for optimized entry. This may be a key feature for using EVs as novel 
nanocarriers for the delivery of therapeutic cargo. 
 
 
???? ??????????????????????????????????????????
Understanding EV-mediated communication in cancer progression and the effects of 
different EV subpopulations is a key feature for designing novel strategies to use EVs as 
carriers for therapeutic cargo. The last study of this thesis addressed the suitability of EV 
subpopulations, including MVs and EXOs, as cancer drug carriers and in the in vitro delivery 
of paclitaxel, an antimitotic cancer drug (publication IV). 
The drug loading efficiency of EVs has been shown to be dependent on the hydrophobic 
nature of the drugs (Fuhrmann et al., 2015). In publication IV, by using passive diffusion, 
MVs and EXOs were loaded with paclitaxel, with an average loading degree of ~ 9.2%, 
independent of the EV concentration used. The paclitaxel loading yield of ~ 21 mg/g EV in 
our study is in accordance with the paclitaxel yield of ~ 7.3 mg/g EV using a similar EV-
loading strategy (Yang et al., 2015). On the other hand, using pre-EV formation methods, the 
paclitaxel-loading yield has been reported to be ~ 2 μg/g EV (Pascucci et al., 2014), which is 
significantly less compared to the drug/EV incubation reported in our study. Similar EV-
loading strategies have been used with other hydrophobic and small therapeutic compounds, 
such as curcumin (Zhuang et al., 2011) and doxorubicin (Jang et al., 2013; Smyth et al., 
2015), facilitating its passage across the membrane. However, these same advantageous 
properties that benefit loading may contribute to the leakage of the drug out of EVs (Smyth et 
al., 2015). Similar amounts of paclitaxel could bind MVs and EXOs in the high or low EV-
concentration containing conditions, with no apparent release of paclitaxel from EVs to the 
media. To date, a limited number of studies have compared the efficiencies of EV subsets as 
drug carriers (Zhuang et al., 2011), and the majority of the studies rely on the delivery of 
drugs within EXOs (Johnsen et al., 2014). 
Interestingly, the EV-mediated cytotoxic effect of paclitaxel was significantly higher 
compared to the effect of the free drug (Figure 12). Although both EV subpopulations 
enhanced the cytotoxic effect of the drug, MVs seemed to be slightly more effective carriers of 
paclitaxel than EXOs, as EXOs required a higher paclitaxel/EXO ratio, whereas MVs had 
comparable cytotoxicity enhancing effect regardless of the paclitaxel/MV ratio used (IV, Fig. 
5). A possible explanation for this could be that the EXOs induced more proliferation of 
cancer cells than MVs, maybe partially counteracting the effect of paclitaxel. Since the exact 
mechanisms are unknown, there is currently no explanation how EVs can enhance the 
cytotoxic effect of paclitaxel. One possible reason could be that EVs can carry more drug into 
the cells than what they can gather from the surrounding media, as shown earlier (Tang et al., 
2012). An alternative explanation could be that EVs deliver the drug into an optimal 
subcellular location, such as the second paclitaxel binding target Bcl-2, promoting apoptosis 
(Ferlini et al., 2009) and thereby enhancing the cytotoxic effect of the drug. 
Importantly, this study showed that the use of MVs and EXOs as drug carriers and 
delivery systems could be advantageous for the administration of chemotherapeutic 
treatments. A lower amount of the drug will be needed in order to achieve the same cytotoxic 
effect, thereby reducing the adverse effects of the treatments. This is a highly relevant aspect, 
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as EV-mediated cancer cell targeting could contribute to decreasing the side effects of the 
drugs (Stremersch et al., 2016a; Tang et al., 2012). Cancer-derived EVs were used as a proof 
of concept model for autologous cancer treatment, since cancer-derived EVs were efficiently 
internalized by cancer cells (Figure 10) and functional studies have demonstrated that 
cancer EVs have a specific cell tropism to their own tumors (Hoshino et al., 2015). While 
exploiting the intrinsic cell targeting properties of cancer-derived EVs could enhance the 
effect of paclitaxel, there may be risks and important limitations to consider before their use 
in in vivo models. As shown in publications III and IV, EVs might prompt increased cell 
viability and proliferation of cells. In the case of cancer treatment, this effect could be 
compensated for by delivering the cytotoxic drug. Hence, the use of EVs from non-cancer 
sources could be of benefit, since they might be capable of reducing the cellular proliferation 
of the tumors while preserving their targeting capabilities (Ohno et al., 2016). In addition, the 
design of artificial nano-size vesicles using the specific targeting moieties of cancer EVs as a 
blueprint will be of benefit in the delivery of therapeutics. Overall, the observations presented 
here suggest that autologous EVs may have potential for the effective delivery of 
chemotherapeutics to cancer cells. However, in vivo models to analyze the targeting and 
pharmacokinetics of the cancer-derived EVs have to be developed in order to evaluate their 
usability in drug delivery. 
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In this thesis, the prospects of cancer-derived EVs in biomarker discovery and drug 
delivery were explored using prostate cancer as a model.  
First, cancer-derived EV subpopulations were shown to have different nucleic acid 
contents, particularly gDNA and mRNA, correlating to specific cellular signatures of their 
parent cells. This work was the first to report that EV subpopulations from prostate cancer 
cells and plasma samples of prostate cancer patients contained double-stranded gDNA 
fragments and that this DNA could harbor differential mutations present in the parent cancer 
cells, emphasizing their potential as future cancer markers. However, the ability to detect 
mutations from biofluids-derived EVs together with the correlation to the patient’s clinical 
parameters needs to be established properly before EVs can be utilized in cancer diagnosis. 
Additionally, differential mRNA levels were found between distinct prostate cancer cell-
derived EV subpopulations, with a unique and distinctive cancer signature identified based 
on the ratio of increased vs decreased mRNAs. Together these findings illustrate the relevant 
and significant translational potential of the combined nucleic acid analysis of EVs to better 
understand and contribute to the diagnosis of prostate cancer.  
Next, the transfer of functional aspects related to the hallmarks of cancer through EVs 
was demonstrated, highlighting the relevant role of EVs in cell-to-cell communication and 
cancer malignancy. The cancer status of the cellular source of the vesicles influences both the 
recognition and internalization capabilities of EVs by cells, promoting alterations of the 
cellular functions towards a more malignant state. 
Finally, cancer cell-derived EV subpopulations were shown to effectively carry and 
deliver a small molecular drug, and to mediate an enhanced cytotoxic effect with a reduced 
drug amount when delivered by EVs. These results showcase the potential for the 
development of a new generation of EV-based drugs, and for the development of new drug 
delivery systems utilizing the beneficial characteristics of EVs. 
Taken together, the results presented in this thesis provide a broad view of the 
possibilities and applications of EVs in cancer research. This thesis will contribute to a better 
understanding of the roles of EVs in intercellular communication and cancer progression, 
and suggests novel diagnostic and therapeutic opportunities for future clinical translation. 
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The extracellular vesicle field has rapidly and exponentially grown in recent years. The 
promising and breakthrough results of multiple studies using EVs in different areas of 
biomedical and translational research have revealed a totally new field in which the multiple 
functions of EVs are now being investigated. Exciting attempts are being made to determine 
the biochemical and biophysical properties of EVs to further improve their detection and 
classification and to deepen the overall understanding of their roles in diseases such as 
cancer. However, several limitations have to be overcome before EVs use can be translated 
from the bench to the clinics. Some technical aspects remain to be clarified, including the EV 
classification and standardized protocols for their isolation, together with reference materials 
for their reliable measurements in clinical and pharmaceutical settings. The developments of 
new technologies that allow the reproducible isolation of large amounts of pure EV samples 
are a crucial need. Another major issue to improve the understanding of the particular 
functions of EVs is the separation of pure and different EV subpopulations of similar size, 
density or composition. New devices or techniques have to be developed to specifically allow 
the capture of a particular kind of EV and to implement single-component EV analysis.  
Despite the remarkable findings in the EV field, the question still remains as to whether 
it is necessary to generate EVs to survive and what is the function of a particular EV subset 
within the heterogeneous EV population. Many of the assumptions regarding the functional 
and mechanistic roles of EVs in intercellular communication need to be further validated 
using in vivo models and well-characterized EV subpopulations. Although the use of 
established cell lines is of great advantage for long-term studies to standardize the EV 
isolation and characterization protocols, the implementation and use of patient’s own 
primary cells and biofluids, although challenging, will provide new insights. Parallel 
comparisons of enzymatically treated vs untreated EVs prior nucleic acid extraction is of 
great importance to better characterize the specificity of the EV cargo and its possible roles 
and function. The combinations of new and traditional “omic” approaches will stratify EV 
subsets based on their unique characteristics, providing new hints about their functionality. 
Additionally, DNA- and RNA-based next generation sequencing studies of EVs isolated from 
the patient’s own biofluids will likely contribute to an earlier diagnosis of various diseases 
such as cancer, by avoiding all the unnecessary invasive procedures and by complementing 
the already existing diagnostic tests. 
Future studies will likely explore in more depth the delivery of therapeutic molecules 
using EVs because of their efficient transfer of proteins, mRNAs, miRNAs, and therapeutic 
drugs into selective targets, which could contribute to the creation of new treatment 
modalities. Improved knowledge on the EV uptake mechanisms and the EV proteins 
responsible for the organ tropism will hence benefit the design of innovative and 
sophisticated drug delivery systems. However, due to the lack of efficient methods for drug 
loading, up-scalable EV production, and bulk preparation, and feasible targeting of selected 
tissues, new EV studies addressing these challenges and questions have to be carried out. The 
increased understanding of the EV biogenesis and processing machinery can be used to 
improve the loading efficiency by engineering the cargo. Additionally, bioinspired EV-
mimicking nanovesicles or similar approaches may represent improved ways to ensure 
sufficient amounts of EVs with efficient drug-loading capacities for clinical use, and a way of 
moving forward in the theranostic field. It is possible that e.g., plant-derived EVs may solve 
the above-mentioned restrictions, since plant-derived EVs may represent a potentially 
unlimited source of EVs for drug delivery.  
Future prospects 
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EVs are rapidly rising as a new independent era in cancer diagnostics and therapies 
with special relevance in personalized medicine. The increasing evidence of the specific cargo 
composition of EVs opens a wide range of new prospects and applications of EVs. With the 
insight gained by standardized and sensitive technologies, many currently unknown 
functions of EV in health and disease will be resolved. 
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